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Abstract 
Cardiovascular heart disease (CHD) is a major health problem worldwide. 
Epidemiological studies show a direct association of CHD with levels of serum total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) but an inverse 
association with high-density lipoprotein cholesterol (HDL-C). Growing evidence 
shows that consumption of soy foods reduces risk of CHD. Isoflavones and their 
glycosides, which are present in soybean, might be responsible for this health benefit. 
However, up to date, the mechanisms by which the soybean isoflavones have such 
health benefit are poorly understood. 
In the present study, the chemical composition and some health benefits of 
soybean isoflavones and their glycosides were investigated. By using column 
chromatography, high performance liquid chromatography (HPLC) and mass 
spectrometry (MS), seven different soybean isoflavones and their glycosides were 
successfully isolated and purified from soybeans. 
The hypocholesterolemic effect of soymilk was firstly examined. Hamsters 
were divided into 3 groups. They were all fed a 0.1% cholesterol diet but they 
drank either water (W) or soybean milk (SM) or cow's milk (CM) as the drinking 
fluid. Serum TC, serum triglyceride (TG)，HDL-C and non- HDL-C were measured. 
It was found that the SM group had lowest levels of TC, TG, non-HDL-C among the 
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three groups. The data suggest that soymilk has the hypocholesterolemic activity at 
least in hamsters. 
Another experiment used ovariectomized hamsters as an animal model in 
determining the estrogenic property of soybean isoflavones. Ovariectomization 
leads to a significant elevation of serum TC because LDL receptor activity is 
drastically decreased in little or absence of estrogen. An oral dose of soymilk 
(OVX-SM) or soybean extract (OVX-SE) had a favorable effect on the serum 
lipoprotein profile. Both soymilk and soybean extract could significant decrease 
serum TC and non-HDL-C，leading to a decrease in the ratio of non-HDL-C to 
HDL-C, in ovariectomized hamsters. In addition, consumption of soymilk and 
soybean extract was associated with a decrease in serum TG. However, soymilk 
and soybean extract had no effect on the concentration of cholesterol in the liver and 
other tissues in these hamsters. These results showed that the hypocholesterolemic 
effect of soymilk and soybean extract may attributable to the estrogenic activity of 
the soybean isoflavones. 
Soybean isoflavones possessed antioxidant activity. The Cu^ "^ - mediated 
human LDL oxidation, ferric reducing ability of plasma (FRAP), and 
1,1 -diphenyl-2-picrylhydrazyl (DPPH) assays, were used to assess the antioxidative 
effects of individual soybean isoflavones and their glycosides. The seven 
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individual soybean isoflavones and their glycosides showed a weaker antioxidant 
activity in Cu^^-mediated LDL oxidation compared with a major tea antioxidant, 
epicatechin. A similar result was also observed in the FRAP assay. For the DPPH 
assay, the seven soybean isoflavones and their glycosides also were less effective in 
free radical-scavenging than a-tocopherol. The present results clearly demonstrated 
that individual soybean isoflavones and their glycosides possessed antioxidant 
activity but the potency was weaker compared with that of epicatechin and 
a-tocopherol. 
In conclusion, soymilk may serve as a health beverage to treat the 
hyperlipidemia patients, especially for the postmenopausal women and individuals 
whose cholesterol level is marginally high not to warrant the prescription of 
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1.1 History of soybean 
The history of soybean {Glycine max L. Merr.) began over five thousand years 
ago on the windy plains of eastern Asia. According to the Chinese tradition, 
soybean was considered the most important cultivated legume and also was one of 
the "Wu Ku" or the five sacred crops named by Chinese emperor Sheng-Nung. 
Historians maintained that Sheng-Nung mentioned soybean in Ben Tsao Gang Mu, 
written in the year 2838 B.C. Others think soybean may have come on the scene a 
bit later, by 300 B.C. Soybean and millet were always mentioned in ancient texts 
as the two major food crops in northern China. 
Once the soybean was cultivated by Chinese farmers, it spread gradually from 
the northern part to the southern part of China, then it spread into Korea, Japan, and 
Southeast Asia. Its spread to Japan was the eighth century A.D. It took one 
thousand years before it traveled west to Europe. 
Soybean yields more usable protein per acre than does any other crop and is far 
more inexpensive protein than do animal foods. In China, with its shortage of 
pastureland and arable farmland, nutrient-rich soybean is an ideal food. Also, the 
Buddhist commitment to vegetarianism has led monks to create soy-based meat 
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substitutes. 
Soybeans have revolutionized the diets of Asian countries. Inventive cooks 
have produced an amazing variety of soy products. The liquid squeezed from 
soaked soybeans has been used by elderly Chinese as an alternative to tea and has 
also been consumed by nursing mothers to stimulate milk production. In more 
recent years, this soymilk has begun to mirror cow's milk. In some Chinese cities, 
factories make early morning soymilk delivery to homes. And not too long ago, in 
Hong Kong, soymilk outsold Coca-Cola. 
1.2 Health benefits of soybean 
Recently, the health effects of soybean have been widely investigated. 
Epidemiological studies indicate that consumption of tofii and other soy foods is 
associated with the low incidence of breast cancer in Japanese women (Adlercreutz 
et al.’ 1991; Adlercreutz, 1998). This discovery has led numerous researchers in 
recent years to search for the biochemical components in soybean that are 
responsible for the cancer risk-lowering effect. It is generally believed that 
isoflavones present in soybean are the active ingredients attributive to such benefit. 
Aside from the potential cancer prevention effect (Kennedy, 1998; Lamartiniere et 
al. 1998; Thiagarajan et al” 1998; Wei et al, 1998; Wu et al, 1998; Pollard and 
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Wolter, 2000), isoflavones have also been found to have other potential health 
benefit, including heart disease prevention (Huff et al, 1982; Wilcox et al, 1995; 
Anthony et al, 1996; Balmir et al, 1996; Anthony et al, 1998; Nilausen and 
Meinertz，1998; Palacio et al, 1998; Potter et al, 1998a and 1998b; Wilson et al, 
1998; Wong et al, 1998; Anderson et al, 1999; Ho et al, 2000 and Merz-Demlow 
et al, 2000)，osteoporosis reduction (Alekel et al, 1998; Arjmandi et al, 1998; 
Williams et al, 1998) and alleviation of postmenopausal syndromes (Knight and 
Eden, 1996). 
1.3 Introduction to flavonoids 
Flavonoids are distributed widely in plant foods such as vegetables and fruits. 
They possess a unique C6-C3-C6 structure (diphenylpropane structure) with varying 
number of phenolic OH groups. More than 4000 different flavonoids have been 
identified. Flavonoids can be classified as various subgroups including flavonols, 
flavones, flavanones, and isoflavones. All of them are structurally related to the 
parent compound, flavone (2-phenylbenzopyrone) (Figure 1.1). 
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Flavonol Isoflavone 
Figure 1.1 Chemical structures of some naturally occurring flavonoids. 
Substituent(s) at position: 
Flavonoid 5 6 7 8 2’ 3’ 4’ 5’ 
Flavones 
Apigenin OH OH OH 
Chrysin OH OH 
Tangeretin OCH3 OCH3 OCH3 OCH3 OCH3 OCH3 
Nobiletin OCH3 OCH3 OCH3 OCH3 OCH3 OCH3 
Flavonols 
Kaempferol OH OH OH 
Quercetin OH OH OH OH 
Galangin OH OH 
Fisetin OH OH OH 
Myricetin OH OH OH OH OH 
Morin OH OH OH OH 
Flavanones 
Naringenin OH OH OH 
Hesperetin OH OH OH OCH3 
Isoflavones 
Biochanin A OH OH OCH3 
Genistein OH OH OH 
Daidzein OH OH  
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1.4 Bioavailability of flavonoids 
The behavior of flavonoids in the digestive tract still remains equivocal. The 
absorption and subsequent distribution, metabolism and excretion of flavonoids in 
humans are poorly understood. Flavonoid glycosides are likely to be hardly 
absorbed in the small intestine because their hydrophilicity lowers solubility in 
micelles. However, the ^ -glucosidase activity of microflora induces the hydrolysis 
of glycosides, resulting in aglycone in the large intestine (Tamura et al., 1980). After 
such a conversion, flavonoids elevate lipophilicity, resulting in high solubility in bile acid 
micelles. A study in rats showed that absorption of rutin (quercetin-3-rutinoside) was 
slower than that of aglycone and quercetin (Manach et al, 1997). This phenomenon 
was explained by the idea that hydrolysis in the large intestine was required for the 
absorption of rutin. However, Hollman et al. (1997) demonstrated that, from an 
experiment involving healthy ileostomy volunteers whose quercetin source resulted from 
the intake of quercetin glucoside-rich onion, quercetin glucosides were absorbed more 
easily than aglycone. His group also found that the quercetin (including metabolites and 
glycosides) level reached a maximum of 0.6 fi M after the intake of fried onion 
(corresponding to 64 mg quercetin) in 2.9 hr (Hollman et al” 1996). Paganga and 
Rice-Evans (1997) claimed that plasma from nonsupplemented humans contained 
quercetin and quercetin glycosides at the level of 0.5-1.6 |liM. Andlauer et al (2000) 
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showed that genistin and its glycoside, was partly absorbed without previous 
cleavage of the p-glycosidic bond. This observation was further confirmed in the 
study of Paganga and Rice-Evan (1997), who found the glycosides of quercetin was 
present in human plasma (Paganga and Rice-Evans, 1997). These studies indicated 
that flavonoid glycosides may be able to enter the human serum and exert their 
effect directly. 
1.5 Chemistry of isoflavones 
Isoflavones are a type of natural flavonoid and possess estrogen-like properties; 
hence they are sometimes referred to as phytoestrogens (Figure 1.2). They would 
likely be metabolized in relativity similar manners as other flavonoids, and therefore, 
may have similar health effects (Lee et al” 1995; Levy et al” 1984; Akiyama et al, 
1987; Adlercreutz et al, 1993; Wang et al, 1994). 
In contrast to flavones, which exist widely in the plant kingdom, isoflavones are 
found predominately in a limited number of plants, such as legumes, particularly 
soybeans. Soy foods are the most important source of dietary isoflavones. 
Isoflavones are not essential nutrients, but they seem to play an important role in 
health maintenance. 
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O ~ Ri 
Ri R2 R3  
Genistein OH H OH 
Genistin OH H 0-Glucose 
Daidzein H H OH 
Daidzin H H 0-Glucose 
Glycitein H OCH3 OH 
Glycitin H OCH3 0-Glucose 
Figure 1.2 The chemical structure of soybean isoflavones. 
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1.6 Estrogenic property of isoflavones 
Isoflavones look very similar to the female sex hormone estrogen. However, 
they are only about one hundred-thousandth as potent as the natural estrogen that is 
present in the blood (Farmakalidis et al, 1985). But even though they are weak, 
they can interfere with the action of the more powerful natural estrogen in several 
important ways. 
Isoflavones can compete the same receptors with estrogen. But when they 
bind to these receptors, they do not produce much of an effect because they are so 
weak. By competing with estrogen for the limited number of receptors, the 
isoflavones prevent estrogen from binding to these receptors. (Peterson and Barnes, 
1991; Peterson and Barnes, 1993; Tang and Adams, 1980). So in the case of 
women, who normally produce a lot of estrogen, the isoflavones can actually act as 
antiestrogens. 
1.7 Nutritional significance of isoflavones and their glycosides 
There are many excellent reviews addressing the potential benefits of 
consuming diets containing isoflavones and their glycosides from soy foods 
(Messina et al, 1994; Knight and Eden, 1996; Adlercreutz and Mazur，1997; Kurzer 
and Xu, 1997; Bingham et al” 1998; Humfrey，1998; Setchell, 1998; Setchell and 
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Cassidy, 1999). These potential beneficial effects include being anticarcinogenic, 
antioxidative, cardioprotective, osteoprotective, neuroprotective and antiangiogenic. 
1.7.1 Anticarcinogenic activity 
Several studies showed that the isoflavones had the anticarcinogenic activity 
(Peterson and Barnes, 1996; Wei et al, 1998; Denis et al, 1999; Griffiths et al, 
1999; Dimas et al, 2000; Mukhtar and Ahmad, 2000; Steele et al, 2000). 
Epidemiologic reports have associated soy isoflavones with a reduced incidence of 
breast and prostate cancers (Lee et al, 1991; Messina et al, 1994; Wu et al, 1998). 
Genistein is one of major isoflavones in soybean. Reports on genistein's 
ability to inhibit tyrosine kinases (Akiyama et al, 1987)，angiogenesis (Fotsis et al, 
1993)，topoisomerase II (Okura et al, 1988)，diacylglycerol synthesis (Dean et al, 
1989)，lipid peroxidation (Jha et al, 1985)，platelet-activating factor and epidermal 
growth factor-induced expression of c-fos (Tripathi et al, 1992)，as well as 
genistein's antioxidant property (Wei et al, 1995), support the claim that genistein 
possesses anticancer activity. Barnes (1995a) showed that genistein decreased 
development of breast tumors in hamsters and slowed the growth of human breast 
cancer cells in vitro. Genistein inhibited both estrogen and growth 
factor-stimulated proliferation of human breast cancer lines MCF-7, T47D ER+ and 
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T47D ER" in culture with IC50 values ranging from 7.0 to 9.4 jiiM/ mL (Peterson 
and Barnes, 1996). Breast cancer growth is regulated by estrogen and peptide 
growth factors, such as epidermal growth factor (EGF), the receptor of which has 
intrinsic protein tyrosine kinase (PTK) activity. Akiyama et al. (1987) showed that 
genistein could act as a specific inhibitor of PTK. Therefore, genistein may block 
mammary epithelial cell growth by interfering with signal transduction events 
stimulated by estradiol or growth factors. Setchell et al (1984) suggested that 
genistein might inhibit tumor cell growth by an antiestrogenic mechanism through 
competition with E2 for occupancy of estrogen receptor (ER). 
Genistein was also shown to inhibit 7, 12-dimethylbenz[a]anthracene (DMBA) 
-induced and 12-0-tetradecanoyl phorbol-13-acetate (TPA)-promoted skin 
carcinogenesis in mice (Wei et al, 1998). 
1.7.2 Antioxidative activity 
Free radicals are chemical species, which have unpaired electrons. They can 
induce oxidation of macromolecules such as lipids, proteins and even DNA 
single-strand breakage. The damage to biosystem is one of the major processes 
that contribute to degenerative diseases such as cancer, cardiovascular disease and 
aging. 
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Antioxidant is a compound which is capable of inhibiting oxygen-mediated 
oxidation of diverse substrates, from simple molecules to polymers and complex 
biosystem. There are two types of antioxidants in general. The first type inhibits 
formation of free radicals, which may initiate oxidation. In most cases they are 
« 
chelators of metal ions. The second type inhibits free-radicals chain-propagation 
reactions. 
The antioxidative activity of isoflavones may be related to the phenol hydroxyl 
groups (Figure 1.3). Phenol hydroxyl groups can scavenge free radicals both in 
vivo and in vitro. Generally, the more hydroxyl groups, the greater the antioxidant 
capacity. Cao et al (1997) suggested that these groups were the chemical basis for 
the antioxidant property of isoflavones. The reduction potential of these groups is 
influenced by the number and their positions on the molecule. Noroozi et al. (1998) 
showed that the aglycons, quercetin, kaempferol, luteolin and myricetin, had a 
greater antioxidative capacity than do the conjugate flavonoids. The high reductive 
capacity of kaempferol in Electron Spin Resonance (ESR) and Fluorescence 
Recovery After Photobleaching (FRAP) assay may be due to the presence of the 
4 ' -0H on the B-ring and the 3-OH on the C-ring (Figure 1.1)，which are connected 
via the 7i-orbital system and interact synergistically. 
The antioxidative activities of these flavonoid compounds may change as a 
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result of solvent effects and pH, which can influence the state of protonation or 
deprotonation of the hydroxy! groups. Therefore, the antioxidant activity of 
isoflavones may differ significantly in various model systems depending on the 
reduction potentials of the hydroxyl moieties relative to that of the oxidizing radical, 
or transition metal ion, used in the system (Mitchell et al, 1998). 
There are many reports discussing the antioxidant activity of isoflavones. 
Some studies showed that flavonoids could inhibit LDL oxidation (Aviram and 
Fuhrman, 1998; Kerry and Abbey, 1998; Zhu et al, 1999, 2000). Kirk et al (1998) 
reported that low-density lipoprotein (LDL) oxidation-mediated by copper ion or 
free radicals was prevented by genistein and daidzein in a concentration-dependent 
manner. 
Apart from the antioxidative ability of isoflavones in LDL, Wei et al (1995) 
showed that genistein and, to a lesser extent, daidzein inhibited H2O2 formation. 
Also, various isoflavones were able to suppress O2' • production by xanthine/ 
xanthine oxidase. Genistein (20 jamol/ L) almost completely inhibited the 
production of O2' •，while daidzein inhibited it by 80% at the same concentration. 
Genistein can also prevent some of the damage to cells caused by H2O2. Genistein, 
like the hydroxyl scavenger dimethylthiourea, could reduce the induction of 
adenylyl cyclase activity by H2O2 in AlO cells (a murine vascular smooth muscle 
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cell line) (Tan et al, 1995) and prevented haemolysis of sheep red blood cells by 
dialuric acid or H2O2 in vitro (Pratt et al, 1981). 
Another report showed that genistein and daidzein could inhibit 
sister-chromatid exchanges of bone marrow cells and DNA adduct formation in 
mouse liver induced by 7,12-dimthylbenz[a]anthracene, a carcinogen (Giri and Lu, 
1995). 
T a T C 11 K • T| A 1 C ^ ^ + RH 
OH O OH 0 
Figure 1.3 Free radical (R ) scavenged by flavonoids 
1.7.3 Cardioprotective activity 
The first epidemiological evidence that the intake of antioxidant isoflavones 
reduced the rate of coronary heart disease mortality was reported in 1993 for elderly 
Dutch men who were followed for five years (Hertog et al, 1993a). Other 
epidemiological data also suggested that dietary isoflavones intake was inversely 
associated with mortality from coronary heart disease (Arai et al, 2000; Ho et al, 
2000). 
Evidence for an independent effect of isoflavones on blood cholesterol 
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concentrations has been demonstrated in rats, hamsters, nonhuman primates and 
humans (Anthony et al, 1996; Balmir et al” 1996; Cassidy et al, 1995; Pelletier et 
al, 1995). LDL oxidation is a critical event in atherogenesis; it promotes the 
formation of foam cells and proliferation of smooth muscle cells. This suggests 
that suppression of LDL oxidation by isoflavones may help prevent atherosclerosis. 
This claim is supported by recent reports indicating that isoflavones could reduce the 
levels of blood lipids including total cholesterol, LDL and apolipoprotein B 
(Anthony et al, 1996，1998; Merz-Demlow et al, 2000). These effects may be due 
to the weak estrogenic property of soy isoflavones (Kuiper et al., 1998), that share 
the LDL reducing and HDL increasing effect with human estrogen (Lilley et al, 
1998; Westerveld, 1998; Godsland, 2001). 
1.7.4 Osteoprotective activity 
Several studies have provided convincing data of the significant improvement 
of bone mass or other endpoints following soy feeding in experimental animals. 
Studies of bone mass in animal models support a biphasic effect of soy isoflavones 
on bone retention, with lower doses having improved skeletal retention of bone mass 
while high doses produce less benefit (Anderson et al, 1998). 
Arjmandi et al, (1996) showed that soy or isoflavone-enriched extracts improve 
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bone mass. Bone mass of ovariectomized rats fed soy protein compared to rats fed 
casein was significantly increased. Arjmandi et al (1998a，b) showed soy 
isoflavones could significantly increase the bone density of ovarian 
hormone-deficient rats. They suggested that the serum alkaline phosphatase 
activity (ALP), an index of bone formation, tended to be higher in soy-fed animals, 
suggesting a positive effect on bone formation. The proposed mechanism is that 
genistein could act as an inhibitor of tyrosine kinases (Akiyama et al, 1987), which 
could directly modulate osteoclastic acid secretion. These acids secreted onto the 
bone matrix can dissolve the bone mineral. This process is under complex control 
related to the maintenance of serum calcium activity and bone strength. Thus, 
substances influencing bone resorption may be a potential antiosteoporotic agent 
(Williams et al, 1998). 
1.7.5 Neuroprotective activity 
One of the first compelling pieces of evidence that postmenopausal estrogen 
replacement might protect against Alzheimer's disease (AD) in elderly women was 
an epidemiological study conducted by Tang et al (1996), who showed a high 
correlation between estrogen use and lowered incidence of AD. In related studies, 
animal experiments demonstrated that ovariectomy-induced estrogen-loss without 
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replacement resulted in a measurable loss of cognitive function, that could be 
essentially prevented by estrogen-replacement (Green and Simpkins, 2000). 
Amyloid p protein (Ap), the major protein component of senile plaque, can 
elicit a toxic effect on neurons. It has been suggested to play an important role in 
pathogenesis of AD. Xu et al, (1998) demonstrated that estrogen inhibited 
Ap generation in cultured neurons. The weak estrogenic property of soy 
isoflavones might mimick the effects of estrogen in neuroprotective actions. 
1.7.6 Antiangiogenic activity 
Angiogenesis, the generation of new capillaries, is virtually absent in the 
healthy adult organism and is restricted to a few conditions including wound healing 
and the formation of corpus luteum, endometrium, and placenta. However, if 
angiogenesis is not tightly regulated, it is obligatory for the growth and progression 
of solid cancers. Fotsis et al (1993) showed that genistein was a potent inhibitor 
of endothelial cell proliferation. Another studies showed that flavonoid might inhibit 
angiogenesis through the inhibition on the secretion of a primary angiogenic 
cytokine, vascular endothelial growth factor, by human prostate and breast cancer 
epithelial cells (Jiang et al, 2000). Therefore, flavonoids may inhibit the growth 
and progression of solid cancers through the inhibitory effect of angiogenesis. 
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Chapter 2 
Composition of Soybean Isoflavones 
2.1 Introduction 
Flavonoids and their glycosides are compounds, which are widely distributed in 
fruits, vegetables and nuts. Naturally occurring flavonoids are classified as 
flavones, flavonols, flavanones, isoflavones and catechins. They are structurally 
related to the parent compound, flavone (2-phenylbenopyrone). The possibility 
that they may play a role in the prevention of several diseases, including cancer 
(Akiyama et al” 1987; Fotsis et al, 1993 and Peterson and Barnes, 1996)， 
cardiovascular disease (Anthony et al, 1998)，and osteoporosis (Arjmandii et al., 
1998)，is receiving great attention. Soy isoflavones are of particular interest. 
Although there have been previous studies on soybeans (Carroll et al, 1978; Potter 
et al, 1993), only recently has more comprehensive information begun to 
accumulate about the soy isoflavones in humans (Xu et al” 1994; Tew et al, 1996) 
and in experimental animals (Supko et al, 1995; King et al, 1996). In order to 
examine the possible roles of soy isoflavones in human health, it is important to 
separate and identify the different isoflavones and their glycosides in soybeans. 
Careful analysis of soy foods with reversed phase HPLC-mass spectrometry 
(HPLC-MS) and extraction protocols in the previous studies showed that most soy 
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foods contained a mixture of isoflavones and their glycosides (Barnes et al, 1994; 
Wang et al, 1994). The composition of isoflavones in soy foods was thought to be 




The present study was to isolate and purify the isoflavones and their glycosides 
from soybeans and to quantify the isoflavones in 19 traditional Chinese foods. 
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2.3 Materials and Methods 
2.3.1 Extraction and isolation 
2.3.1.1 Preparation of soybean butanol extract 
Dried soybean powders (3 kg) were extracted with 18 liters of 70% ethanol 
three times at 6 0 � C. Ethanol was evaporated under vacuum in a rotary evaporator 
to yield 1550 g of ethanol extract, which was then dissolved in 2 liters of distilled 
water. Then the ethanol extract was partitioned with chloroform in a ratio of 1:1 
for three times. The chloroform fraction was dried down under vacuum to yield 
298 g of chloroform extract. The remaining ethanol extract was further partitioned 
with butanol in a ratio of 1:1 for three times. The butanol and water fractions were 
dried down under vacuum to yield 78 g of butanol extract and 1080 g of water 
extract. 
2.3.1.2 Preparation of isoflavones and their glycosides from soybean butanol 
extract 
In brief, 78 g of soybean butanol extract was fractionated in a column packed 
with Sephadex LH-20 (100 |liM, Pharmacia Fine Chemical Co., Ltd., Germany) and 
eluted with 5 liters of 70% ethanol (250 mL each time) to produce twenty fractions 
(F1 to F20). Fractions F1 to F6 and F17 to F20 contained mainly sugars, organic 
acids and some other components that had no UV absorption, while F7 - F16 
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contained mainly a mixture of glycosides. The total weight of the fractions F7 to 
F16 was 32 g. Each fraction of F7- F16 was then loaded onto a Sephadex LH-20 
column. Pure ethanol was used to elute the column. The elutes were monitored 
using a high performance liquid chromatography (HPLC) equipped with a UV 
detector. These fractions containing isoflavones or glycosides were then loaded 
onto a CI8 HPLC preparative column (Hypersil ODS，250 x 22mm, 10 ^im, Alltech, 
Deerfield, IL, USA) and eluted with 10% acetonitrile in 1% acetic acid solution, 
leading to purification of eight compounds. These glycosides were identified using 
their ultraviolet (UV) and mass spectrophotometry (MS). The purity of these 
flavonoid glycosides and genistin was greater than 95%, based on HPLC analysis. 
2.3.2 HPLC analysis 
2,3,2.1 Sample preparation for the HPLC analysis 
All wet samples were freeze-dried before the HPLC analysis. One gram of 
dried, finely ground samples was placed in a 100 mL conical flask containing 40 mL 
of methanol, 20 mL of 0.1 N HCl and 0.2 mL of flavone (11.25 mM in methanol). 
The mixture was sonicated for 10 minutes and then stirred at room temperature for 2 
hours using a magnetic stirrer. Extractants were centrifuged at 850 g for 10 
minutes. The supernatant of sample was filtered through a 0.45 |j,m PTEE filter 
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[poly(tetrafluoroethylene), Alltech Associates Inc., Deerfield, IL, USA]. The 
supernatant was transferred into a 1.5 mL sample vial (Hewlett Packard, Palo Alto, 
CA, USA) and then subjected to HPLC analysis. 
2.3.2.2 HPL C an alysis 
All the isoflavones and their glycosides were analyzed using a Hewlett Packard 
series 1100 HPLC (Hewlett Packard, palo alto, CA, USA) equipped with a binary 
pump delivery system (G1322A) and a diode array detector (G1946A). 
In brief, 10 jjJL of the supernatant was loaded onto a CI8 column (Hypersil 
ODS, 4.6 X 250 mm, 5 Waters, Ireland) through an autosampler (G1313A). 
The diode array detector was set from 200 to 400 nm, and the eluting components 
were monitored at 260 nm. The quantitative analysis of the isoflavones and their 
glycosides were carried out according to the method of Wang and Murphy (1994) 
with some modifications. The mobile phase consisted of 1% acetic acid in water 
(v/v) (solvent A) and acetonitrile (solvent B). After injection of the sample, solvent 
B was increased from 10 to 20% in 40 min and then increased from 20 to 100% in 
the next 30 min. The flow rate was maintained at 0.8 mL/ min. The typical 




































































































2.3.2.3 Quantification of the isoflavones and their glycosides 
The flavonoids and their glycosides were quantified by comparing area 
responses with those of authentic standard by the method as described in part 2,3.1.2. 
Authentic standards for genistein, glycitein and daidzein with purity higher than 98% 
were obtained from Sigma Chemical Company (St. Louis, MO, USA). The 
concentrations of malonyl and acetyl glycosides of genistein, glycitein and daidzein 
were calculated from the curves for corresponding P-glycosides, corrected for 
molecular weight differences since the molar extinction coefficient of the esterified 
isoflavone is similar to that of the p-glycosides (Barnes et al, 1994). 
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2.4 Results 
2.4.1 Structural Identification 
The eight compounds were identified by studying their various spectra of UV 
and mass spectrometry. The results were compared with those obtained from 
Barnes et al. (1994) and the authentic standards of various isoflavones and their 
glucosides in soybeans. The characteristics of each compound were described 
below. 
2.4.1.1 Compound 1 
Compound 1，was isolated as a yellow amorphous powder, m.p. 233-235 °C, 
[ a ] % -36.4 (0.02M, KOH). The [M+l]+ peak at m/z 417 in the APCI-MS 
(Atmospheric Pressure Chemical Ionization- Mass Spectrometry), indicated that the 
formula weight was 416. The APCI-MS spectrum of compound 1 revealed a peak 
at m/z 255 [M-glucosyl+l]+，suggesting that compound 1 was a glycoside containing 
sugar. The UV absorption was maximum at 256 nm. After the comparison, 
compound 1 was deduced as daidzin with the percentage composition of C 60.58%; 
H 4.84%; O 34.58% and molecular formula C21H20O9. (Figure 2.2). 
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2.4.1.2 Compound 2 
Compound 2, was isolated as a yellow amorphous powder, m.p. 192-195 °C， 
[af^D -13.4 (c, 3.65 in DMF). The [M+l]+ peak at m/z 447 in the APCI-MS 
(Atmospheric Pressure Chemical Ionization- Mass Spectrometry), indicated that the 
formula weight was 446. The APCI-MS spectrum of compound 2 revealed a peak 
at m/z 285 [M-ghicosyl+l]+，suggesting that compound 2 was a glycoside containing 
sugar. The UV absorption was maximum at 259 nm. After the comparison, 
compound 2 was deduced as glycitin with the percentage composition of C 59.19%; 
H 4.97%; O 35.84% and molecular formula C22H22O10. (Figure 2.2). 
2.4.1.3 Compound 3 
Compound 3，was isolated as a yellow amorphous powder, m.p. 254-256�C, 
[aJ^ ^D -27.7 (MeOH aq.). The [M+l]+ peak at m/z 433 in the APCI-MS 
(Atmospheric Pressure Chemical Ionization- Mass Spectrometry), indicated that the 
formula weight was 432. The APCI-MS spectrum of compound 3 revealed a peak 
at m/z 271 [M-glucosyl+l]+，suggesting that compound 3 was a glycoside containing 
sugar. The UV absorption was maximum at 263 nm. After the comparison, 
compound 3 was deduced as genistin with the percentage composition of C 58.34%; 
H 4.66%; O 37.00% and molecular formula C21H20O10. (Figure 2.2). 
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2.4.1.2 Compound 2 
Compound 4, was isolated as a yellow amorphous powder, m.p. 168 °C, 
[a]D -45.2 (c, 0.2 in DMSO). The [M+l]+ peak at m/z 503 in the APCI-MS 
(Atmospheric Pressure Chemical Ionization- Mass Spectrometry), indicated that the 
formula weight was 502. The APCI-MS spectrum of compound 4 revealed a peak 
at m/z 255 [M-glucosyl+l]+’ indicating that compound 4 was a glycoside containing 
sugar. The UV absorption was maximum at 258 nm. After the comparison, 
compound 4 was deduced as 6"-0-malonyldaidzin with the percentage composition 
of C 57.37%; H 4.41%; O 38.21% and molecular formula C24H22O12. (Figure 2.2). 
2.4.1.5 Compound 5 
Compound 5, was isolated as a yellow amorphous powder, m.p. 162 °C. The 
[M+l]+ peak at m/z 533 in the APCI-MS (Atmospheric Pressure Chemical 
Ionization- Mass Spectrometry), indicated that the formula weight was 532. The 
APCI-MS spectrum of compound 5 revealed a peak at m/z 285 [M-ghicosyl+l]+, 
indicating that compound 5 was a glycoside containing sugar. The UV absorption 
was maximum at 260 nm. After the comparison, compound 5 was deduced as 
6"-0-malonylglycitin with the percentage composition of C 56.39%; H 4.54%; O 
39.06% and molecular formula C25H24O13. (Figure 2.2). 
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2.4.1.2 Compound 2 
Compound 6，was isolated as a yellow amorphous powder, m.p. 145 °C. The 
[M+l]+ peak at m/z 519 in the APCI-MS (Atmospheric Pressure Chemical 
Ionization- Mass Spectrometry), indicated that the formula weight was 518. The 
APCI-MS spectrum of compound 6 revealed a peak at m/z 271 [M-gkicosyl+l]+, 
indicating that compound 6 was a glycoside containing sugar. The UV absorption 
was maximum at 260 nm. After the comparison, compound 6 was deduced as 
6"-0-malonylgenistin with the percentage composition of C 55.60%; H 4.28%; O 
40.12% and molecular formula C24H22O13. (Figure 2.2). 
2.4.1.7 Compound 7 
Compound 7，was isolated as a yellow amorphous powder, m.p. 330 °C. The 
[M+l]+ peak at m/z 255 in the APCI-MS (Atmospheric Pressure Chemical 
Ionization- Mass Spectrometry), indicated that the formula weight was 254. The 
UV absorption was maximum at 249 nm. After the comparison, compound 7 was 
deduced as daidzein with the percentage composition of C 70.86%; H 3.96%; O 
25.17% and molecular formula C15H10O4. (Figure 2.2). 
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2.4.1.2 Compound 2 
Compound 8, was isolated as a yellow amorphous powder, m.p. 302 °C. The 
[M+l]+ peak at m/z 263 in the APCI-MS (Atmospheric Pressure Chemical 
Ionization- Mass Spectrometry), indicated that the formula weight was 262. The 
UV absorption was maximum at 263 nm. After the comparison, compound 8 was 
deduced as genistein with the percentage composition of C 66.67%; H 3.73%; O 
29.60% and molecular formula C15H10O5. (Figure 2.2). 
2.4.2 Quantification of isoflavones in traditional Chinese foods 
The isoflavones in 20 samples, including soybean and 19 other traditional 
Chinese foods (Tables 2.1)，were quantified as previously described in parts 2.3.2.1 
and 2.3,2.2 from the standard curves of their authentic standards or their pure 

















































































































































































































































Table 2.1 The compositions of isoflavones in some food samples (mg/g). 
Daidzin Genlstin 寸’’二"叫 一 G e n i s t e i n . J ^ v l s 
Hard Tofu 0.91 ±0 .02 1.10 ±0.02 0.91 土 0.02 1.24 ±0.03 0.08 士 0.00 0.07 ±0.01 4.22 ±0.01 
Soft Tofu 0.17 土 0.03 0.23 ±0.01 0.18 士 0.02 0.28 土 0.01 0.04 ±0.03 0.04 士 0.01 0.94 ±0.01 
^ ^ S f d ^ " 0 .44±0.01 0 .48±0.01 0 .19±0.03 0 .24±0.01 0.02土 0.01 0 .02±0 .00 1.39 ±0.01 
Soybean 0.25 士 0.00 0.32 土 0.01 1.01 土 0.02 1.38 土 0.02 0.00 ±0 .00 0.01 ±0 .00 2.97 ±0.03 
niopb Turtle 
Bean 0.56 ±0 .02 0.84 土 0.01 0.77 土 0.01 1.13 ±0.01 0.08 土 0.00 0.07 ±0 .00 3.45 士 0.01 
Soy Milk 0.92 ±0 .02 1.46 ±0 .02 0.00 土 0.00 0.00 ±0 .00 0.07 土 0.01 0.06 ±0.00 2.51 ±0 .02 
^BeanMUk^ 0.87 ±0.01 1.40 土 0.02 0.00 ±0 .00 0.00 土 0.00 0.11 ±0.01 0.10 ±0.01 2.48 士 0.02 
MilkCVk^o") 0.42士0 . 0 2 0.67土0.01 0.00士0.00 0.00土0.00 0.02土0.00 0.03 土0.00 1.14土0.01 
Mated Soy 
Bean Milk 0.34 士 0.02 0.52 ±0.03 0.00 ±0 .00 0.00 土 0.00 0.04 士 0.00 0.03 ±0 .00 0.93 ±0 .02 
(Vitasoy)  
Curb^Clot 1.00 土 0.01 1.86 士 0.03 0.00 ±0 .00 0.00 士 0.00 0.13 ±0 .00 0.00 士 0.00 2.99 ±0.01 
^'s^J'uce^" 0 .00±0 .00 0.00土0.00 0.00土0.00 0 .00±0 .00 0.15 ±0 .02 0.09士0.00 0.24士0.01 
Bean Curb 0.00 ±0 .00 0.00 土 0.00 0.00 ±0 .00 0.00 ±0 .00 0.06 士 0.00 0.10 ±0 .00 0.16 士 0.01 
Soy Sauce 0.00 土 0.00 0.00 ±0 .00 0.00 ±0 .00 0.00 ±0 .00 0.06 ±0.01 0.08 士 0.01 0.14 ±0 .00 
ADZUKI 0.00 土 0.00 0.00 ±0 .00 0.00 ±0 .00 0.00 ±0 .00 0.00 士 0.00 0.00 ±0 .00 0.00 士 0.00 Bean 
^^Bean^^ 0.00 ±0 .00 0.00 土 0.00 0.00 土 0.00 0.00 土 0.00 0.00 士 0.00 0.00 ±0 .00 0.00 ±0 .00 
Chick Peas 0.00 土 0.00 0.00 土 0.00 0.00 士 0.00 0.00 土 0.00 0.00 土 0.00 0.00 土 0.00 0.00 士 0.00 
Red Bean 0.00 ±0 .00 0.00 ±0 .00 0.00 ±0.00 0.00 ±0 .00 0.00 士 0.00 0.00 ±0 .00 0.00 ±0 .00 
R e d ^ ^ j n e y o.OO 士 0 . 0 0 0 . 0 0 ± 0 . 0 0 0 . 0 0 ± 0 . 0 0 0 . 0 0 ± 0 . 0 0 0 . 0 0 ± 0 . 0 0 0 . 0 0 ± 0 . 0 0 0 . 0 0 士 0 . 0 0 
Green Bean 0.00 ±0 .00 0.00 ±0 .00 0.00 士 0.00 0.00 ±0 .00 0.00 士 0.00 0.00 土 0.00 0.00 土 0.00 
Baked Bean 0.00 士 0.00 0.00 ±0 .00 0.00 土 0.00 0.00 ±0 .00 0.00 ±0 .00 0.00 土 0.00 0.00 ±0 .00 
Data are expressed as mean 土 S.D. (n=3) 
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2.5 Discussion 
Soybean, hard tofu, soft tofu, sweet bean curd and black turtle bean contained a 
mixture of 6"-0-malonylglucoside conjugates and /3 -glucoside conjugates together 
with the aglycone conjugates (Figure 1, Table 2.1). Soybean and black turtle bean 
contained predominantly 6"-0-malonylglucoside conjugates (Table 2.1). Soymilk, 
black turtle bean milk, soy bean milk (Vitasoy), mated soya bean milk (Vitasoy) and 
soybean curb clot, which were prepared by high heat treatment, contained 
predominantly /3 -glucoside conjugates but no 6"-0-malonylglucoside conjugates 
were found (Table 2.1). This is in agreement with the previous study by Lori，et al. 
(1998)，who demonstrated that hot aqueous extraction, used to produce tofu or 
soymilk, resulted almost entirely in the formation of 曰-glucoside conjugates. Black 
bean sauce, bean curb and soy sauce, prepared by high heat treatment together with 
fermentation, contained only aglycone conjugates (Table 2.1). ADZUKI bean, 
black eye bean, chick peas, red bean, red kidney bean, green bean and baked beans, 
which were not soy based foods, contained no isoflavones (Table 2.1). 
This study showed that the glucoside composition of soy foods was determined 
by the processing conditions. They are easily altered during different treatments. 
Isoflavones are mainly found in soybeans as well as black turtle bean as their 
6"-0-malonylglucoside conjugates. Aqueous heating and extraction, used to 
32 
produce tofU，soymilk or soybean curb clot, led to the conversion of 
6"-0-malonylglucoside conjugates to (3 -glucoside conjugates. The result 
demonstrated that the 6"-0-malonylglucoside conjugates were unstable when they 
were exposed to heat. Room temperature extraction also led to a loss of 
6"-0-malonylglucoside conjugates, but at a much slower rate (Coward et al., 1993). 
Fermentation, used to produce black bean sauce, bean curb or soy sauce, causes 
conversion of both 6"-0-malonylglucoside conjugates and jS -glucoside conjugates 
to their aglycones (Table 2.1). The total isoflavone concentration in the food would 
not be reduced under normal cooking condition, however, their glucoside 
composition might be altered (Coward et al., 1993). 
The composition of the glucoside conjugates may have significant effects on the 
bioavailability and pharmacokinetics of the isoflavones. In general, most studies on 
soy isoflavones in vitro or in animal models were carried out by using the aglycones. 
Whereas in most clinical trial, soy foods were the source of isoflavones that 
contained almost exclusively glucoside conjugates. The present study showed that 
the composition of the isoflavone glucoside conjugates varied from one food to 
another. Furthermore, different treatments or cooking procedures may alter their 
glucoside conjugates. Because the composition of the isoflavone glucoside 
conjugates may affect the rate of absorption and possibly the degree of further 
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metabolism, alterations in the chemistry of isoflavones need to be taken in account 
when the data from clinical trials are interpreted. 
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Chapter 3 
Hypocholesterolemic Effects of Soymilk in 
Hamsters 
3.1 Introduction 
3.1.1 Lipoproteins and their functions 
Most of the cholesterol in plasma is transported in 3 major lipoproteins namely: 
very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and 
high-density lipoprotein (HDL) (Superko, 2001). VLDL, one of the major 
triglyceride carriers in the blood, is synthesized and secreted from the liver. After a 
series of interactions with the enzyme lipoprotein lipase, the VLDL particles become 
more dense and relatively cholesterol rich. An intermediate density lipoprotein 
(IDL) precedes the appearance of LDL, which is normally the greatest source of 
cholesterol transport among the lipoproteins. The role of LDL is to transport 
cholesterol from the liver to the peripheral tissues. In contrast to LDL, the HDL 
synthesized in the liver is the main vehicle for the transfer of cholesterol from plasma 
and the peripheral tissues back to the liver for catabolism (Eckardstein et al, 1998, 
2001; Stein and Stein, 1999; McNamara, 2000). 
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3.1.2 Risk factors of cardiovascular disease 
A major medical disorder of the twenty-century was coronary heart disease 
(CHD), which was the leading cause of death in many developed countries. Over 
the past 40 years, epidemiologic studies showed that blood levels of serum total 
cholesterol (TC) and LDL cholesterol (LDL-C) are directly related to cardiovascular 
disease (LaRosa et al, 1990; Carleton et al, 1991). Cholesterol accumulation in 
the artery is accompanied by the development of atherosclerosis (Brown and 
Goldstein, 1986). It has been demonstrated that high serum cholesterol is a single, 
independent factor associated with CHD (Rifkind & Lenfant，1986). However, it is 
found that high cholesterol level is not an absolute prerequisite for the development 
of atherosclerosis (Hamilton, 1997). LDL is the major cholesterol carrier in the 
blood. LDL initiates the sequence of events leading to advanced atherosclerosis. 
These events include the entering of monocytes into intima and the development of 
foam cells. However, recent evidence suggests that LDL itself may not be the 
prime culprit, but it needs to be oxidatively modified before being taken up by the 
monocyte-derived macrophages (Steinberg, 1997; Parhami et al, 1993; Diaz et al, 
1997; Young et al, 2001). As the amounts of LDL cholesterol in the blood increase, 
the chance of oxidation will increase. Therefore, the amount of LDL cholesterol 
present in the blood can be used as one of the index for the risk of cardiovascular 
36 
disease (Hamilton, 1997; Ballantyne, 1998). 
Several prospective studies have found an inverse relationship between HDL 
cholesterol (HDL-C) concentration and CHD incidence. This is independent of 
total or LDL cholesterol concentrations (Backer et al” 1998; Boden et al, 2000a， 
2000b; Despres et al, 2000). This may be due to the reversal cholesterol transport 
of HDL from peripheral cells and plasma back to the liver for catabolism 
(Eckardstein et al, 1998，2001; Kwiterovich, 1998; Philips et al, 1998). As a result, 
the effect of reversal cholesterol transport of HDL can prevent the accumulation of 
cholesterol in plasma and decrease the chance of atherosclerosis. In addition to 
LDL-C, the ratio of LDL-C to HDL-C or non-HDL-C to HDL-C is also commonly 
used as an assessment of the risk of cardiovascular diseases. 
It is still an open issue that high level of serum triglyceride (TG) is an 
independent risk factor for CHD (Hulley et aL, 1980). Several studies have shown 
that serum TG is not associated with the risk of CHD independently (Holme et aL, 
1985). For instance, TG does not appear to be significantly associated with CHD in 
a multivariate analysis (Rhoads et al, 1978; Holme et al, 1985). 
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3.1.3 Hamster as an animal model of cholesterol metabolism 
Golden Syrian hamster {Mesocricetus Auratus) has been used widely as an 
experimental animal model in studying and estimating the efficacy of 
hypocholesterolemic agents in humans (Sugiyama et al, 1995; Campos et al, 1998; 
Terpstra et al, 1998; Trautwein et al, 1998，1999; Ntanios and Jones, 1999; 
Schneider et al, 2000). The plasma cholesterol distribution in hamster is similar to 
that in humans, the major cholesterol carrier in hamster is LDL (Nistor et al, 1987). 
As determined by electrophoresis in agarose gel, it was found that about 50% of 
plasma cholesterol in hamsters occurs in the LDL fraction (Nistor et al, 1987). 
Also hamsters are similar to humans in biliary sterol secretion (Spady and Dietschy, 
1985; Bocan and Guyton, 1985). Moreover, intrinsically low rates of hepatic 
cholesterol synthesis are found in both humans and hamsters. It is because 
increased hepatic influx of absorbed cholesterol could not be compensated in the 
species by down-regulation of cholesterol synthesis, but may alter hepatic cholesterol 
excretion (Berr et al., 1993). Rat is another common laboratory testing animal, 
however, they lack the cholesteryl ester transfer protein and are resistant to 
developing atherosclerosis due to high cholesterol feeding, while hamsters are like 
humans and are susceptible to atherosclerosis (Bok et al” 1999). 
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3.2 Objective 
Soymilk is a favourite and commonly consumed beverage in China. It is now 
gaining popularity in Hong Kong. Although soybean has been shown to reduce 
plasma cholesterol in humans (Anthony et al, 1998; Nilausen and Meinertz, 1998; 
Potter et al” 1998; Wong et al, 1998)，the hypocholesterolemic effects of soymilk 
have not been thoroughly examined. The objective of this experiment was to 
examine the hypocholesterolemic activity of soymilk in hamsters. 
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3.3 Materials and Methods 
3.3.1 Preparation of soymilk 
Most commercial soymilks in the market contain additives, which may have 
influence on plasma cholesterol in hamsters. Therefore, soymilk was freshly 
prepared. In brief, 260 g (dry weight) of soybeans were soaked in one liter of water 
at room temperature for 8 hours. The soaked soybeans were then put into a 
soymilk-making machine (Tanisho Soyabean Maker TY-800A3, China) together with 
1300 mL of 100 °C water, producing soymilk with concentration of 0.2g/ mL 
soybean. The resultant soymilk was diluted to O.lg/ mL by mixing with additional 
1300 mL of 100 °C water and then cooled at room temperature. 
3.3.2 Animals 
Male Golden Syrian hamsters were housed (3- 4 hamsters per cage) in an 
animal room at 25 °C with 12:12-h light-dark cycles. Fresh 0.1% cholesterol diets 
were given daily. Food intake was measured daily and body weight was recorded 
twice a week. The hamsters were allowed access to food and fluid ad libitum. 
3.3.2.1 Experiment one - Hypocholesterolemic effect of soymilk in hamsters 
Hamsters (125- 140 g，n=36) were randomly divided into 3 groups. They were 
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fed a 0.1%-cholesterol diet (Glen Forrest Stockfeeds, Western Australia, Australia). 
The energy content was listed in Table 3.1. The pellet is in 5 mm diameter. To 
minimize changes during the storage, the diets were stored at 4 °C. 
The control group was given the distilled water. The second and the third 
group of hamsters were given soymilk (SM) and cow's milk (CM) as drinking fluids， 
respectively. 
At the end of week 4, all hamsters were sacrificed after overnight fasting. 
Blood was collected via the abdominal aorta. After clotting, the blood was 
centrifuged at 1500 g for 10 minutes and serum was collected. The livers, brains, 
kidneys and hearts were removed, washed with saline, and stored at - 8 0 � C. 
3.3.2.2 Experiment two - The effect of fluid cross-over between soymilk and 
cow^s milk on serum cholesterol in hamsters 
Hamsters (125- 140 g, n=36) were randomly divided into 3 groups. They were 
similarly fed a 0.1%-cholesterol diet (Glen Forrest Stockfeeds, Western Australia, 
Australia). The control group was given the distilled water throughout the entire 
experiment. The second group was given soymilk for 8 weeks and then switched 
to cow's milk for additional 4 weeks (S-C group). The third group was given 
cow's milk for 8 weeks and then switched to soymilk for additional 4 weeks (C-S 
group). 
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Blood was collected at week 4 after overnight fasting from the ophthalmic 
venous plexus. At the end of 12 weeks, all hamsters were sacrificed after overnight 
fasting. Blood was collected via the abdominal aorta. After clotting, the blood 
was centrifuged at 1500 g for 10 minutes and serum was collected. 
3.3.3 Serum lipid and lipoprotein determinations 
Serum TG and TC levels were determined using enzymatic kits (Sigma 
Chemical, St. Louis, MO, USA). HDL-C was measured after precipitation of LDL 
and VLDL with phosphotungstic acid and magnesium chloride, using a commercial 
kit (Sigma). 
3.3.4 Determination of cholesterol in the organs 
The liver (300 mg)，brain (150 mg), kidney (300 mg) and heart (300 mg) were 
used to determine the cholesterol level. In brief, the tissue sample and 1 mg 
stigmastanol, as an internal standard, were homogenized in 15 mL 
chloroform-methanol (2:1, v/v) and 3 mL saline. The chloroform-methanol phase 
was removed and dried down under a gentle nitrogen steam. After 1 hour mild 
hydrolysis with 5 mL NaOH in 90% ethanol at 90 °C, 1 mL of water and 6 mL of 
cyclohexane were added for extraction of cholesterol. The cyclohexane phase was 
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evaporated to dryness under nitrogen, and cholesterol was converted to its TMS-ether 
derivative by a commercial TMS-reagent (dry pyridine-hexamethyldisilazane-
trichlorosilane, 9: 3: 1，v/v/v, Sil-A regent, Sigma). After 1 hour at 60 °C, the 
mixture was removed under a gentle stream of nitrogen. The TMS-ether derivative 
was dissolved in 600 )iL of hexane, and after centrifugation, the hexane phase was 
transferred to a vial for gas-liquid chromatograph (GLC) analysis. The TMS-ether 
derivative was analyzed in a fused silica capillary column (SAC^^-S, 30 m x 0.25 
mm, i.d.; Supelco, Inc., Bellefonte, PA, USA) in a Shimadzu GC-14B GLC equipped 
with a flame-ionization detector (Shimadzu). The column temperature was set at 
285°C and maintained for 20 minutes. Helium was used as carrier gas at a head 
pressure of 22 psi. A typical GLC chromatogram of liver cholesterol is shown in 
Figure 3.1. 
3.3.5 Statistics 
Data are expressed as mean 士 standard deviation (SD). The group means were 
statistically analyzed using one-way analysis of variance (ANOVA) and Student's 
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Figure 3.1 Gas liquid chromatographic profile of cholesterol in the liver 
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Table 3.1 Composition of hamster diets 
Protein 19.1% 
Fat 12.30/0 




Digestible Energy 15.5 MJ/Kg 
Lard lOOg/Kg 
Cholesterol Ig/Kg 
(adapted from Glen Forrest Stockfeeders) 
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3.4 Results 
3.4.1 Experiment one - Hypocholesterolemic effect of soymilk in 
hamsters 
3.4.1.1 Growth and food intake 
The body weight gain and food intake of hamsters are shown in Table 3.2. No 
significant differences in body weight, fluid intake and food intake were observed 
among the control, SM and CM group. 
3.4.1.2 Effect ofSM and CM on serum TG, TC and HDL-C 
After hamsters were given with different fluids for 4 weeks, their serum TG, TC 
and HDL-C were measured. There were no significant differences in serum TG and 
TC between the SM group and the control while a significant increase was observed 
in CM group (Table 3.3). 
A significant increase in HDL-C by 15.9% and 35.2% was observed in the SM 
group and CM group, respectively, compared with the control group (Table 3.3). 
3.4.1.3 Effect ofSM and CM on non-HDL-C and ratio ofnon-HDL-C to HDL-C 
Non-HDL-C was defined as a difference between TC and HDL-C. 
Non-HDL-C levels for the control, SM and CM groups were 63.2 士 17.2，42.2 ±21.3 
and 66.0 士 18.2 mg/ dL，respectively. A significant reduction in non-HDL-C by 
33% compared with that in the control was observed in the SM group (p< 0.05). In 
contrast, a significant increase in non-HDL-C by 56% compared with that in the SM 
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group was seen in the CM group (p< 0.05) (Table 3.3). The ratio of non-HDL-C to 
HDL-C in the SM group was found to be significantly lower than those of the control 
and the CM groups (Table 3.3). 
3.4.1.4 Effect of SM and CM on concentration of hepatic cholesterol 
The liver weights of the hamsters were measured immediately after the hamsters 
were killed. The hepatic cholesterol contents in the control, SM and CM groups 
were 104.1 土 16.8，92.2 士 16.4 and 63.8 士 11.3 mg/ g of liver, respectively. It was 
found that the hepatic cholesterol concentrations were significantly different among 
the three groups (Figure 3.2). 
3.4.1.5 Effect of SM and CM on brain，heart and kidney cholesterol 
There was no significant difference in brain，heart and kidney cholesterol 
content among the three groups (Figure 3.3). 
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Table 3.2 Effect of soymilk (SM) and cow's milk (CM) on body weight and food 
intake in hamsters in experiment one 
Control SM CM 
Initial body wt (g) 131.3 ±7.1 126.5 ± 5.9 125.7 ±9.1 
Final body wt (g) 161.5 ±6.6 159.4 ±8.0 162.1 ±8.5 
Fluid intake (mL/ day) 25.2 士 5.6 24.2 ±8.1 27.1 士 6.3 
Food intake (g/ day) 7.2 ±1.7 6.8 ± 1.4 6.6 土 1.0 
Data are expressed as mean 土 S.D., n= 12 
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Table 3.3 Effect of fluid intake on serum TG, TC, HDL-C, non-HDL-C and the ratio 
of non-HDL-C to HDL-C 
Control SM CM 
TG (mg/ dL) 152.0 ± 63.4b 139.7 ±36.0& 259.6 ± 72.5a 
TC(mg/dL) 140.6 ± 23.5b 131.9 士 170.7 ± 23.6a 
HDL-C (mg/ dL) 77.4 土 15.9' 89.7 士 19.lb 104.7 士 17.0a 
Non-HDL-C (mg/ dL) 63.2 土 17.2b 42.2 士 21.3� 66.0 土 18.2' 
Non-HDL-C/ HDL-C 0.71 ±0.11" 0.48 士 0.24b 0.65 土 0.22" 
Data are expressed as mean 土 S.D.，n= 12 
SM: Soymilk group 
CM: Cow's milk group 
Non-HDL-C = [TC] - [HDL-C] 
Means at the same row with different superscripts (a,b，c) differ significantly at 
p< 0.05 
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Control SM group CM group 
Figure 3.2 Effect of soymilk (SM) and cow's milk (CM) on concentration of 
hepatic cholesterol in hamsters. Data are expressed as means 士 S.D.， 
n= 12. Means with different superscript letter (a, b) differ significantly 
at p< 0.01 
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Figure 3.3 Effect of soymilk (SM) and cow's milk (CM) on concentration of tissue 
cholesterol levels in hamsters. Data are expressed as means 士 S.D.，n= 
12. 
51 
3.4.2 Experiment two - The effect of fluid cross-over between 
soymilk and cow's milk on serum cholesterol in hamsters 
3.4.2.1 Growth and food intake 
The body weight gain and food intake of hamsters are shown in Table 3.4. No 
significant differences in body weight, fluid intake and food intake were observed 
among the control, S-C and C-S groups. 
3.4.2.2 Effect of fluid cross-over on serum TC 
After the fluid cross-over at week 8, their serum total cholesterol was measured 
at week 12. There was a significant increase in serum TC in the S-C group by 
64.2% (p< 0.01) and a significant decrease in serum TC in the C-S group by 24.3% 
(p< 0.01) before and after the fluid cross-over (Figure 3.4). 
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Table 3.4 Effect of fluid intake on body weight and food intake in hamsters in 
experiment two 
Control S-C Group C-S Group 
Body wt at week 0 (g) 151.7 土 13.2 140.0 ±10.8 138.8 ±6.1 
Body wt at week 8 (g) 155.4 ±9.2 146.2 土 11.2 142.9 ±6.9 
Body wt at week 12 (g) 155.0 土 11.3 152.2±13.2 157.5 ± 10.6 
Fluid intake (mL/ day) 
Week 0-8 26.3 ± 8.2 28.6 ± 8.9 29.2 ± 6.8 
Week 9-12 25.9 ± 10.2 29.8 ±9.6 27.5 ± 5.9 
Food intake (g/ day) 
Week 0-8 6.8 土 2.1 6.5 ±1.5 5.9 ±2.2 
Week 9-12 7.0 ±1.7 6.2 ±1.3 6.5 ±1.9 
Data are expressed as mean 士 S.D.，n= 12 
Control: Distilled water 
S-C group: Soymilk for 8 weeks followed by cow's milk for 4 weeks. 
C-S group: Cow's milk for 8 weeks followed by soymilk for 4 weeks. 
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Figure 3.4 Effect of fluid cross-over on serum total cholesterol in hamsters. 
Data are expressed as means 士 S.D., n= 12. 
Control: Distilled water 
S-C group: Drank soymilk for 8 weeks followed by cow's milk for additional 4 
weeks. 
C-S group: Drank cow's milk for 8 weeks followed by soymilk for additional 4 
weeks. 
Means with different superscript letter (a, b) differ significantly at p< 0.01 
Means with different superscript letter (c，d) differ significantly at p< 0.01 
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3.5 Discussion 
Soymilk is an aqueous extract of whole soybeans. It contains soy protein and 
isoflavones, which are thought to have an anti-atherogenic effect (Anthony et al, 
1996). Evidence for an independent effect of isoflavonoids on blood cholesterol 
concentrations has been demonstrated in rats，hamsters, nonhuman primates and 
humans (Anthony et al, 1996; Balmir et al, 1996; Cassidy et al, 1995; Clarkson et 
al, 1998; Pelletier et al, 1995). It has been reported that genistein is absorbed 
more rapidly than its glucoside (King et al., 1996). Soymilk contains higher levels 
of the P-glucosides form rather than aglycones (Lori et al, 1998). The purpose of 
the present study was to find whether soymilk was effective in lowering blood 
cholesterol. 
The present study demonstrated that drinking soymilk could decrease serum TG 
and TC compared with drinking cow's milk. Also, drinking soymilk was associated 
with a significant decrease in the ratio of non-HDL-C to HDL-C compared with the 
control. In contrast, drinking cow's milk increased serum TG and TC, accompanied 
with an increase in the ratio of non-HDL-C to HDL-C compared with drinking 
soymilk. The hypocholesterolemic activity of soymilk compared with cow's milk is 
also reflected from the observation that serum TC was decreased when the hamsters 
were switched from cow's milk to soymilk. These findings suggest that drinking 
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soymilk could cause the redistribution of serum cholesterol. The non-HDL-C to 
HDL-C ratio is commonly used as a risk factor of cardiovascular disease. The 
higher the ratio, the greater the risk of cardiovascular diseases. If the data could 
apply to humans, the decrease in the ratio of non-HDL-C to HDL-C indicated that 
drinking soymilk might be associated with a decreased risk of cardiovascular 
diseases. 
The mechanisms why soy products can decrease risk of cardiovascular diseases 
are still under investigation. Potential mechanisms by which soymilk induce 
lowering of blood cholesterol concentrations include thyroid status, bile acid balance 
and the estrogenic effects of genistein and daidzein. Some other studies also point 
out that isoflavones exhibit antioxidant properties and have favorable effects on 
arterial compliance. 
Previous studies showed that supplementation of soy-protein could significantly 
increase the HDL-C and decreased the ratio of LDL-C to HDL-C, but TC was not 
significantly reduced in humans (Nilausen and Meinertz, 1998). This is in 
agreement with the result in the present study, implying that some components 
present in both soymilk and soybean might be responsible for the observed effect. 
A previous study showed that supplementation of soy isoflavones in the diet could 
decrease non-HDL-C and increase HDL-C (Anthony et al” 1998). Since, genistein 
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can bind to estrogen receptors (Kuiper et al, 1998) to exert estrogenic activity and 
may share the LDL reducing and HDL increasing effect of human estrogen (Lilley et 
al” 1998; Westerveld, 1998; Godsland, 2001). Therefore, soy isoflavones may be 
one of the active ingredients which were responsible for the observed activity. 
The present results showed that there was a decrease in the hepatic cholesterol 
in the SM group. Dietary soy protein has been reported to enhance bile acid 
excretion in rabbits and rats (Potter, 1996). Although an increase in the serum 
HDL-C might increase the rate of cholesterol transported form the peripheral parts of 
the body back to the liver for degradation, the rate of bile acid synthesis by the liver 
might be higher than the rate of the cholesterol entering into the liver, leading to a 
decrease in hepatic cholesterol. However, the mechanism by which drinking cow's 
milk was also associated with a decrease in hepatic cholesterol remains unclear. It 
is known that saturated fatty acids in cow's milk down-regulate hepatic 
LDL-receptor, thus elevating serum cholesterol level and lowering hepatic 
cholesterol content. In fact, serum non-HDL-C in cow's milk group was elevated 
and hepatic cholesterol was decreased compared with the control and soymilk group. 
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Chapter 4 
Antioxidant Activities of Soybean Isoflavones 
and Their Glycosides 
4.1 Introduction 
A major medical disorder nowadays is cardiovascular disease. It is the leading 
cause of mortality in Western populations (Grundy, 1990; Martin et al., 1986). It is 
responsible for about half of the deaths in the developed countries and its incidence 
in developing countries is increasing. The underlying cause of coronary heart 
disease, stroke and peripheral arterial disease is mainly atherosclerosis. Oxidation 
of low density lipoprotein (LDL) is implicated in the development of atherosclerosis 
and dietary antioxidants may provide a useful therapy in the prevention of LDL 
oxidation and atheroma development. In recent years, there has been a great 
interest in health effect of dietary antioxidants on coronary heart disease 
(Parthasarathy et al. 1998). 
Atherosclerosis is thought to be a degenerative disease that is an inevitable 
consequence of aging. The harmful effect of atherosclerosis is mainly on the large 
and medium-sized arteries. The arterial wall has three layers namely innermost 
layer, tunica intima, tunica media and tunica adventitia. The intima is normally a 
thin layer but it becomes greatly thickened when an atherosclerotic lesion forms. 
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The formation of atherosclerotic lesions may last over a period of years or decades, 
but their bulk can impede the flow of blood through the arteries. Most heart attacks 
(myocardial infarctions) are due to the sudden Assuring of an atherosclerotic lesion. 
These fissures cause blood to come into contact with substances inside the lesions 
that cause a thrombus and block the flow of blood (Wilcox et al, 1995)，leading to a 
myocardial infarction if the artery supplies the muscles of the heart. 
4.1.1 Role of low density lipoprotein oxidation in the development of 
atherosclerosis 
The oxidative theory of atherosclerosis proposes that the oxidized LDL is 
atherogenic in the arterial wall rather than the LDL itself (Diaz et al, 1997 and 
Young et al, 2001). LDL enters the arterial wall from the plasma and accumulates 
in the extracellular subendothelial space of arteries. Through the action of resident 
vascular cells, the LDL is mildly oxidized to a form known as minimally modified 
LDL. This minimally modified LDL induces local vascular cells to produce 
monocyte chemotatic protein, which stimulates monocyte recruitment and 
differentiation to macrophages in arterial walls (Parhami et al, 1993). The 
accumulating monocytes and macrophages stimulate further peroxidation of LDL. 
In contrast to the uptake of native LDL by the LDL receptor on macrophages, 
the uptake of oxidized LDL by the scavenger-receptor pathway is not subject to 
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negative-feedback regulation. The aldehydes formed during LDL oxidation can 
combine with the epsilon-amino groups of the lysyl residues of apo B-lOO to form 
Schiff bases. When a Schiff base forms, the normal positive charge of the lysyl 
residue is abolished and the LDL particles acquire a greater negative charge 
(Steinbrecher, 1987). As a result, the oxidized LDL can no longer be recognized by 
the native LDL receptor and thus results in massive uptake of cholesterol (from 
oxidized LDL) by the macrophages (Diaz et al, 1997). The amount of cholesterol 
in LDL entering the cells is thought to overwhelm the capacity of the macrophages to 
release it and the cholesterol therefore accumulate inside the cells, converting them 
into foam cells (Figure 4.1). The oxidized LDL also has direct chemotactic activity 
for monocytes and stimulates the binding of monocytes to the endothelium. The 
monocytes will become trapped in the subendothelial space, if they cross the 
endothelial layer. This is because that the oxidized LDL can inhibit their egress 
from the arterial wall (Quinn et al, 1987). 
In the later lesions, deposition of extracellular cholesterol esters forms a large 
pool of lipids at the base of the lesions. Then proliferation of smooth muscle cells 
in the intima will occur and these smooth muscle cells will secrete large amounts of 
collagen, which adds bulk to the lesions. The macrophages die in the deeper parts 
of the lesions, mainly at the edge of the lipid pool in advanced lesions. Therefore, 
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oxidation of LDL is highly related to atherosclerosis. 
4.1.2 LDL oxidation 
LDL can be oxidatively modified in a cell-free system by transition metals such 
as iron and copper and by all the major cells of the arterial wall such as endothelial 
cells, smooth muscle cells, and monocyte-macrophages (Jialal & Devaraj, 1996). 
The mechanisms by which these cells oxidize LDL are poorly understood. 
Involvement of superoxide (Steinbrecher et al, 1988; Hiramatsu et aL, 1987) and 
lipoxygenase (Parthasarathy et al, 1989; Rankin et al, 1991) have been proposed. 
Another proposed mechanism is that cells might oxidize LDL by releasing the 
thiol-containing amino acid cysteine (Heinecke, 1987). Oxidation of cysteine leads 
to form cystine in the extracellular space, producing sulf- or oxygen centered free 
radicals that may attack LDL. When cysteine is oxidized to cystine, iron (III) may 
be reduced to iron (II) while copper (II) is converted to copper (I). These transition 
metal ions in their lower valency states may oxidize LDL better than in their higher 
valency states (Heinicke et al, 1998). 
Whatever the mechanism is, oxidation of LDL will involve the abstraction by an 
unidentified free radical of a hydrogen atom from a methylene (CH2) group of a 
polyunsaturated fatty acid (PUFA). Molecular rearrangement of the resulting 
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unstable carbon radical results in a more stable configuration, a conjugated diene. 
The conjugated diene reacts very quickly with molecular oxygen, and the peroxyl 
radical thus forms a crucial intermediate. The PUFA peroxyl radical in LDL may 
abstract a hydrogen atom from an adjacent PUFA to form a hydroperoxide and 
another lipid radical, a reaction which results in chain propagation. The fragments 
of lipid hydroperoxides will eventually break down into shorter-chain aldehydes and 
other products, including malondialdehyde (MDA) and 4-hydroxynonenal (Figure 
4.2) (Young et al, 2001) 
4.1.3 Thiobarbituric acid reactive substances (TEARS) as an index 
of LDL oxidation 
Measurement of TEARS formation is a most frequently used test as an index of 
lipid peroxidation. A breakdown product of lipid peroxidation, malondialdehyde 
(MDA), is formed when lipid hydroperoxide is decomposed during LDL oxidation 
(Figure 4.2). These MDA molecules react with thiobarbituric acid (TBA) in acidic 
condition to form a pink chromagen, which has an absorption maximum at 532 nm. 
The amount of these chromagen can be quantified by spectrophotometrically or 
fluorometrically (Ohkawa et al, 1978). This method is sensitive to determine the 
degree of lipid peroxidation. 
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Oxidative Modifications of LDL and Atherosclerosis 
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Figure 4.1 Macrophage-mediated oxidation and aggregation of LDL, and formation 
of foam cells. Native LDL particles migrated into the extracellular 
subendothelial space and then oxidized by the adjacent cells. The 
oxidized LDL was taken up by the macrophages. Cholesterol esters in 
oxidized LDL enter the macrophages and overwhelm their capacity to 
release them. These cholesterol esters therefore accumulate inside the 
cells, converting them into foam cells (Adapted from Aviram et al” 1998). 
CE: Cholesterol ester 
SMC: Smooth muscle cell 
Ox-LDL: Oxidized LDL 
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Figure 4.2 Basic reaction sequence of lipid peroxidation (Adapted from Young, 2001 
with some modifications) 
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4.1.4 The ferric reducing ability of plasma (FRAP) as a measure of 
"antioxidant power" 
A simple test measuring the ferric reducing ability of plasma, the FRAP assay, is 
presented as a novel method for assessing "antioxidant power". At low pH, when a 
ferric-tripyridyltriazine (FE'"-TPTZ) complex is reduced to the ferrous (Fe") form, 
an intense blue color with absorption maximum at 593 nm develops (Benzie 1996; 
Liu et al. 1982). In the assay, excess Fe"^ is used, and the rate-limiting factor, color 
formation of Fe"-TPTZ is due to the reducing ability of the sample. 
4.1.5 l,l-cliphenyl-2-picrylhydrazyl (DPPH) as a measure of free 
radical scavenging capacity 
In this assay, antioxidants react with DPPH (which gives a strong absorption at 
517 nm) and produce a colorless 1,1 -diphenyl-2-picrylhydrazyl (Saracoglu et al 
2002). The change of absorbance produced in this reaction has been widely used to 
test the ability of a natural antioxidant to scavenge the free radical. 
4.1.6 Antioxidant and LDL oxidation 
The major lipid-soluble antioxidant present in LDL is vitamin E (a-tocopherol). 
It is a chain-breaking antioxidant and traps peroxyl free radicals. Enrichment of 
vitamin E has been shown to retard LDL oxidation and inhibit the proliferation of 
smooth muscle cells (Chan, 1998). A cross-sectional study of 16 European 
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populations also showed a significant inverse correlation between serum vitamin E 
concentrations and coronary heart disease (CHD) mortality (Grey et al., 1991). 
Some natural antioxidants, for example, flavonoids may protect vitamin E in 
LDL, either by scavenging free radicals themselves or by regenerating vitamin E 
from its radical form (Zhu et al” 1999). Some studies showed that a mixture of 
flavonoid, a-tocopherol and ascorbic acid might inhibit LDL oxidation 
synergistically (Negre et al., 1995; Hwang et al., 2000). 
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4.2 Objective 
The objective of the present study was to examine the antioxidative potency of 
individual soybean isoflavones and their glycosides by using Cu^ "^ - mediated human 
LDL oxidation, FRAP and DPPH as three different assay models. 
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4.3 Materials and Methods 
4.3.1 Preparation of samples 
Seven individual soybean isoflavones and their glycosides, including genistein, 
genistin, 6"-0-malonylglycitin, 6"-0-malonylgenistin, daidzein, daidzin and glycitin, 
were extracted and purified by the method described in part 2.3.1. All of them were 
obtained with purity higher than 95%. Authentic standards for flavone and 
epicatechin (EC) were obtained from Sigma Chemical Company (St. Louis, MO, 
USA); a-tocopherol was obtained from ICN Biomedicals Inc. (USA). 
4.3.2 Isolation of LDL from human serum 
Human serum was collected from healthy subjects at the Prince of Wales 
Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. To prevent 
lipoprotein modification, EDTA and NaN^ were added to the serum collected (final 
concentrations of EDTA and NaN^ were 0.1% and 0.05%, respectively). LDL was 
isolated from the serum according to the method described previously (Havel et al” 
1995). In order to prevent LDL from oxidation, the centrifuge tubes containing 
serum were flushed with nitrogen gas. Firstly, the serum was centrifuged at 1500 g 
for 15 minutes to remove cells and cell debris. NaCl-KBr solution (dissolve 153 g 
NaCl, 354 g KBr and 100 |Lig EDTA in one liter of water, 1.33 g/ mL) was then added 
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to increase the density to 1.019. The serum was re-centrifuged at 160,000 g for 20 
hours at 4 � C . After the removal of the top layer containing chylomicron and very 
low-density lipoprotein (VLDL), the density of remaining serum fractions was 
increased to 1.064 and re-centrifuged at 160,000 g for an additional 24 hours at 4 °C. 
The top LDL fraction was collected and then flushed with nitrogen and stored at -70 
°C. The protein content of isolated LDL was determined using Lowry's method 
(Lowry et al., 1951). 
4.3.3 LDL oxidation 
The stock LDL fraction (7.43 mg protein/ mL) was dialyzed against 100 
volumes of the degassed dialysis solution (pH = 7.4) containing 0.01 M sodium 
phosphate, 0.9 % NaCl, 10 \xM EDTA and 0.05% NaNs in dark at 4 � C for 24 hours. 
The dialysis solution was changed four times. Oxidation of LDL was conducted as 
previously described by Puhl et al. (1994). LDL protein (100 ^ig) was incubated in 
a mixture containing 5 fj,M CuSO^ at 37 °C for up to 24 hours. The oxidation of 
LDL was then stopped by addition of 25 [iL of 1.0% EDTA and cooled at 4 °C • 
4.3.4 TBARS assay 
The degree of LDL oxidation was monitored by measuring the production of 
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TBARS as previously described (Buege & Aust，1978). After the reaction was 
stopped by addition of EDTA at 4 °C, 2 mL of 0.67% thiobarbituric acid and 15% 
trichloroacetic acid in 0.1 N HCl solution were added to the LDL-incubated tube. 
The incubation mixture was then heated at 95 °C for 1 hour, cooled on ice, and 
centrifuged at 1000 g for 20 minutes. The formation of TBARS was determined by 
measuring the absorbance at 532 nm. Calibration was done with a MDA standard 
solution prepared from tetramethoxylpropane. The extent of LDL oxidation was 
expressed as nmol MDA/ mg LDL protein. 
4.3.5 FRAP assay 
The FRAP assay was performed according to the procedures described by 
Benzie et al. (1996) with some modifications. In brief, the reagents used included 
300 mmol/ L acetate buffer, pH 3.6 [3.1 g sodium acetate and 16 mL of acetic acid 
per liter of buffer solution]; 10 mmol/ L TPTZ (2, 4，6,-tripyridyl-s-triazine, Sigma, 
Switzerland) in 40 mmol/ L HCl (BDH，England) and 20 mmol/ L FeCls • 6H2O 
(Pancreac, Spain). Working FRAP reagent was prepared freshly by mixing acetate 
buffer, TPTZ solution and ferric solution in the 10: 1: 1 ratio. Standard Aqueous 
solution of known Fe" concentration, in the range of 100-5000 |imol/ L (FeS04 • 
7H2O, Riedel de Haen, Germany), were used for calibration. 
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Freshly prepared FRAP reagent (1000 |aL) was warmed to 37 °C and a reagent 
blank reading was taken at 593 nm; 20|iL of sample was then added. Absorbance 
readings were monitored immediately using UV spectrophotometer (Shimadzu, 
UV-1601，Tokoy, Japan) up to 10 min. An absorbance change becomes constant 
before 8 min and the reaction is completed by 8 min after sample-reagent mixing, so 
8 min readings were selected for calculation of FRAP values. The change in 
absorbance between the 8 min reading and the blank reading was calculated for each 
sample according to the Fe" standard solution. Samples and standard solutions 
were always analyzed in duplicates in a "forward-then-reverse" ordering in order to 
eliminate the experimental error. 
4.3.6 DPPH assay 
The DPPH assay for free radical scavenging effect was adapted from Blois 
(1958) with a slight modification. Briefly，0.3 mL test samples and 0.2 mL 
methanol were mixed with 2.5 mL of 75 M DPPH in a cuvette. After shaking, the 
mixture was incubated for 90 min in darkness at room temperature and then 
absorbances were measured at 517 nm using an UV spectrophotometer (Shimadzu, 
UV-1601, Tokoy, Japan). The difference in absorbance between a test sample and a 
control (methanol) was taken. This activity is given as % DPPH radical-scavenging. 
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Two positive controls were executed with a-tocopherol (ICN Biomedicals Inc., USA) 
and epicatechin (Sigma Chemical Company, USA). 
4.3.7 Statistics 
Results were expressed as mean 士 standard deviation (S.D.). Student's t-test 
and one-way analysis of variance (ANOVA) were used for statistical evaluation of 
differences between groups (SigmaStat version 2.01，SigmaStat Advisory Statistical 
Software, MO, USA). 
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4.4 Results 
4.4.1 Effects of seven individual soybean isoflavones and their 
glycosides on LDL oxidation 
Effects of soybean isoflavones and their glycosides on production of TEARS 
was examined by incubating human LDL in the presence of 5 |j,M CUSO4 as an 
oxidation initiator. As shown in Figure 4.3, the control LDL was significantly 
oxidized within 3 hours. Flavone at the concentrations of 12 |j,M demonstrated no 
or little protection to LDL from Cu2+ -mediated oxidation (Figure 4.3). On the other 
hand, the positive control LDL in the presence of 12 |LIM epicatechin (EC), a major 
antioxidant present in tea drinks, did not oxidize until 18 hours incubation. (Figure 
4.3). Seven soybean isoflavones and their glycosides at a concentration of 12 |j.M 
showed different potency on the protection to LDL from Cu2+ -mediated oxidation 
(Figure 4.3). The LDL was oxidized completely within 5 hours in the presence of 
glycitin and diadzin, within 9 hours in the presence of daidzein, within 11 hours in 
the presence of both 6"-0-malonylgenistin and 6"-0-malonylglycitin and within 17 
hours in the presence of genistin and genistein (Figure 4.3). 
4.4.2 The antioxidant power of individual soybean isoflavones and 
their glycosides in the FRAP assay 
The order of the FRAP values was epicatechin > genistin > daidzin > 
6"-0-malonylgenistin > 6"-0-malonylglycitin > glycitin > genistein > daidzein > 
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flavone. The FRAP values of these isoflavones and their glycosides showed a 
dose-dependent manner at concentrations ranged from 4 |iM to 12 \iM. 
4.4.3 Activity of individual soybean isoflavones and their glycosides 
as radical scavenging antioxidants 
The radical scavenging activity of the isolated isoflavones and their glycosides 
from soybeans, epicatechin, a-tocopherol and flavone was estimated by their 
reactivity with DPPH. The addition of 12 |iM of each compound to DPPH caused a 
rapid decrease in absorbance at 517 nm. Except for the two positive controls, 
epicatechin and a-tocopherol, genistin showed the highest DPPH radical-scavenging 
activity followed by daidzin (Figure 4.5). All the other compounds demonstrated 
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Figure 4.3 Inhibitory effects of epicatechin, flavone, isoflavones and their 
glycosides isolated from soybeans on the production of thiobarbituric 
acid reactive substances (TEARS) in Cu2+-mediated oxidation of human 
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Figure 4.4 FRAP values of epicatechin, flavone, isoflavones and their glycosides 
isolated from soybeans. Data are expressed as mean 士 S.D. of n= 3. 
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Figure 4.5 Comparison of DPPH radical-scavenging activities of epicatechin, 
a-tocopherol, flavone, isoflavones and their glycosides isolated from 
soybeans. Data are expressed as mean 士 S.D. of n= 3. 
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4.5 Discussion 
Soy-based food is one of the most widely consumed foods in the Asian 
countries, especially in the Mainland China. Isoflavones are one of the major 
components in soybean. They occur predominantly as biologically inactive 
B-glycosides (Setchell, 1998). After ingestion, the glycosides of genistin and 
daidzin are hydrolyzed by bacteria to release the bioactive phytoestrogens genistein 
and daidzein (Kurzer and Xu, 1997). Many studies have demonstrated that both 
genistein and daidzein have strong antioxidant activity in vitro. There is little 
information on the relative antioxidant activity of other isoflavones and their 
glycosides. 
Oxidative stress in the body can damage the macro-molecules like DNA, 
proteins and lipids, and might be involved in atherosclerosis (Holvoet et al, 1998; 
Heinecke, 1998)，cancer (Keum et al, 2000; Mukhtar et al, 2000; Steele et al； 2000) 
and chronic inflammation (Halliwell, 1994). In atherosclerosis, for example, 
oxidation of low-density lipoproteins is thought to play an important role (Hamilton, 
1997; Young et al, 2001). It has been hypothesised that the flavonoid antioxidants 
may protect tissue against damage caused by free radicals (Aviram et al. 1998). 
The present study examined the protective effect of soybean isoflavones and 
their glycosides against the Cu -mediated LDL oxidation. It clearly demonstrated 
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that the individual soybean isoflavones and their glycosides, especially the genistein 
and genistin, could inhibit the LDL-oxidation. This result is in agreement with 
pervious studies conducted by Hodgson et al (1996); Rifici et al (1994); Tsai & 
Chait (1995), who have demonstrated antioxidant effect of soybean isoflavones in 
copper or cell-mediated oxidation of LDL and serum. 
Generalizing the data from the Cu^''-mediated LDL oxidation test, the 
antioxidative activities of individual soybean isoflavones tested were in the order of 
genistein > genistin > 6"-0-malonylglycitin > 6"-0-malonylgenistin > daidzein > 
daidzin > glycitin. The different protective effects may be due to the different 
number and location of the aromatic hydroxyl groups (Chen et al” 1996). However, 
their inhibitory effects on LDL-oxidation were not as strong as that of EC, which has 
been shown to be potent antioxidant present in the tea drinks. 
Vitamin E (a- tocopherol) is a major lipid soluble antioxidant present in LDL. 
Depletion of endogenous vitamin E would lead to LDL oxidation (Diaz et al. 1997). 
Regeneration of vitamin E by the secondary antioxidant can inhibit LDL oxidation 
and decrease the rate of atherosclerosis (Hamilton, 1997). Soybean isoflavones and 
their glycosides may function as a primary antioxidant by directly reducing the 
formation of free radicals mediated by Cu^ "^ . They may spare and maintain the level 
of vitamin E and thus delay the onset of lipid peroxidation. 
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A previous study by Rice-Evans et al (1996) suggested that hydroxyl groups are 
necessary for isoflavones to have antioxidant activity. In the present study, 
genistein showed the strongest antioxidant activity among the individual isoflavones 
and their glycosides. One possibility is that the C-4 carbonyl group and the double 
bond between C-2 and C-3 of the C ring exert anti-peroxidative activity (Figure 1.1) 
(Cook and Samman, 1996). One may assume that isoflavone molecules are 
positioned at the surface of the LDL particle in such a way that the fatty acyl residues 
are interspersed with the fatty acyl residues of phospholipid monolayer. The ring 
structure with the unsaturated C-ring on the lipoprotein surface facing the aqueous 
phase would be anchored to the lipid layer by the fatty acyl carbon chains. For 
other isoflavones and their glycosides, the smaller number of hydroxyl group or the 
bulky molecule attached on the A-ring results in lesser potency (Figure 2.2). 
For the ferric reducing ability of plasma (FRAP) assay, the results demonstrated 
that individual soybean isoflavones and their glycosides had potent antioxidant 
properties in vitro. They could significantly reduce the ferric-tripyridyltriazine 
(FEUI-TPTZ) complex to the ferrous (Fe") form in a dose-dependent manner. 
Generalizing the data from the FRAP assay, the "antioxidant power" of individual 
soybean isoflavones tested were in the order of genistin > daidzin > 
6"-0-malonylgenistin > 6"-0-malonylglycitin > glycitin > genistein > daidzein. 
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The result was slightly different from that of the Cu^'"-mediated LDL oxidation test 
above. This may be due to the "steric effects" of the hydroxyl groups that may 
behave differently in the media of Cu^'"-mediated LDL oxidation and the FRAP 
assay. 
Although antioxidant activity of isoflavones has been reported in several studies 
by measuring indirect parameters such as oxidative damage to lipids, proteins and 
DNA (Harper et al, 1999; Ruiz et al” 1999), their direct scavenging activity against 
a variety of reactive oxygen and nitrogen species is largely unknown. In the present 
study, the radical-scavenging activities of soybean isoflavones and their glycosides 
were also determined using the DPPH assay. The assay showed similar results with 
the FRAP assay. The two positive controls, epicatechin and a-tocopherol, had the 
highest radical-scavenging activity. Among the soybean isoflavones, genistin gave 
the greatest radical-scavenging activity, followed by daidzin, 6"-0-malonylgenistin 
and 6"-0-malonylglycitin. Genistein, glycitin and daidzein showed the lowest 
radical-scavenging activity. This result is in agreement with that of Sato et al 
(1992) and Mitchell et al (1998)，who demonstrated genistein and daidzein did not 
strongly scavenge DPPH or galvinoxyl radicals. 
By comparing the results in DPPH assay with those of the FRAP assay, some 
soybean isoflavones, such as daidzin, 6"-0-malonylgenistin and 
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6"-0-malonylglycitin, showed different "antioxidant power" in the two assays. In 
addition, genistin showed relatively higher DPPH radical-scavenging activity, but it 
demonstrated a lower antioxidant activity in the Cu^^-mediated LDL oxidation. 
These results may suggest that DPPH radical-scavenging activity can be used as an 
indication of potential antioxidant activity, but it may not always correlate linearly 
with other assays. The activity of putative antioxidants has been attributed to 
various mechanisms namely prevention of decomposition of peroxides, prevention of 
hydrogen abstraction, and radical scavenging (Diplock, 1997). 
It is concluded that individual soybean isoflavones and their glycosides possess 
antioxidant activities. However, their antioxidant capacity was much weaker 
compared with that of epicatechin and a-tocopherol. 
82 
Chapter 5 
Hypocholesterolemic Effects of Soybean 
Isoflavones in Ovariectomized Golden Syrian 
Hamsters 
5.1 Introduction 
5.1.1 Coronary heart disease in women 
Coronary heart disease in women is often diagnosed later and treated less 
aggressively than that in men. One of three women aged 65 or older and 1 of 9 
women aged 45-64 will develop clinical evidence of CHD (Wenger, 1995). Yet 
many women and some physicians still do not recognize CHD as a serious health 
risk to women. Women and men share many of the same risk factors for CHD, but 
the degree of risk often differs. The pattern of risks may also vary with age. A 
man's risk of heart attack typically begins to increase at age 40-45. A woman's risk 
starts to rise sharply about 10 years later - after menopause at about age 50-55. 
Women ultimately catch up with men, as the CHD risk continues to rise among 
women in their 70s and 80s. Women tend to be 10-15 years older than men when 
they first presentation with symptomatic CHD, and this may partly account for their 
high death rates. 
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5.1.2 Menopause as a risk factor in CHD 
Menopause, whether natural or surgical, is the CHD risk factor unique to 
women. In natural menopause, a woman's estrogen level decreases over the course 
of several years, and, therefore, her risk of CHD begins to increase somewhat even 
before she actually stops menstruating. Estrogen may protect against CHD through 
its effects on serum cholesterol levels, clotting factors, the vasculature, and 
endothelial cells and possibly myocardial function. Estrogen increases HDL 
cholesterol level and decreases LDL cholesterol level, lowers fibrinogen level, is a 
weak antioxidant, and has some calcium channel blocking activity. Estrogen is also 
a vasodilator and can cause even atherosclerotic arteries to dilate in response to 
appropriate stimuli by normalizing endothelial function. As a result, menopause is 
associated with elevations of circulating TC and LDL-C concentrations, placing 
postmenopausal women at great risk for CHD (Bruschi et aL, 1996; Fukami et al., 
1995; Goldstein and Stampfer，1995; Sullivan, 1996). These changes are a 
consequence of reductions in the level of circulating estrogen, which is the basis for 
estrogen replacement therapy (ERT). ERT reduces the risk of CHD in part through 
the modulation of serum cholesterol (Godsland et aL, 1987; Knight and Eden, 1996). 
However, ERT and other cholesterol-lowering pharmacological agents may be 
accompanied by some side effects (U.S. Department of Health and Human Services 
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1993) and therefore are recommended only for women without known 
contraindications. Moreover, many women chose not to comply with a 
recommendation for ERT because of safety concerns (Kessel, 1998). Therefore, 
other means that present no side effects for the treatment of postmenopausal 
hypercholesterolemia are preferred. 
5.1.3 Dietary soy in treatment of postmenopausal hyper-
cholesterolemia 
The potential benefits of dietary soy in the prevention and treatment of chronic 
diseases, namely heart disease and cancer, have long been known. Soy protein, 
isoflavones, phospholipid, and phytate have been investigated as components 
responsible for the anti-atherogenic effect of soy, although the mechanism was not 
completely established (Sugano et al” 1993; Anthony et al., 1996; Knuiman et al,, 
1989; Jariwalla et al, 1990). 
The cloning and description of a novel estrogen receptor, ER-p (Kuiper et al, 
1996), has made it possible to understand the selective effects of structurally closely 
related estrogenic substances. The primary soy-derived isoflavones, genistein and 
diadzein，have weak estrogenic activity, and their functions as both estrogen agonists 
and antagonists in vitro have been reported (Mathieson & Kitts，1980). They both 
bind to ERs, a finding probably explained by their structural similarity with estrogen. 
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According to Kuiper et al (1998), the binding affinity of genistein to the recently 
discovered ER-P was about 20 times greater than to ER-a. Compared with 
estradiol, the binding affinity of genistein for ER-a was 4%, and for ER-p was 87% 
(Kuiper et al, 1998). Compared with estradiol, the binding affinity of daidzein for 
ER-a and ER-P was 0.1 and 0.5%, respectively (Kuiper et al, 1998). 
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5.2 Objective 
The hypocholesterolemic activity of soymilk was previously demonstrated in 
hamsters. The objective of the present study was carried out further to examine the 
hypocholesterolemic activity of isoflavones in soymilk and soybean extract by using 
the ovariectomized Golden Syrian hamsters as an animal model. 
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5.3 Materials and Methods 
5.3.1 Preparation of soymilk 
Soymilk was prepared as previously described in Chapter 3 (3.3.1) with some 
modification. In brief, 260 g (dry weight) of soybeans were soaked in 1000 mL of 
water at room temperature for 8 hours. The soaked soybeans were then put into a 
soymilk-making machine (Tanisho Soyabean Maker TY-800A3, China) together with 
1300 mL of 1 0 0 � C water, producing soymilk with concentration of 0.2g/ mL 
soybean. The soymilk was concentrated to 1.0-1.5 mg total isoflavones/ mL 
using a freeze-drier. The isoflavones content were determined as previously 
described in Chapter 2 (2.3.2.3). 
5.3.2 Preparation of soybean extract 
Soybean extract was prepared as previously described in Chapter (2.3.1.1) with 
some modification. In brief, dried soybean powders (3 kg) were extracted with 18 
liters of 70% ethanol three times at 60 °C. Ethanol was evaporated under vacuum 
in a rotary evaporator. The extract was then dissolved in 2 liters of distilled water 
and partitioned with chloroform in a ratio of 1:1 for three times. The chloroform 
was removed and the remaining aqueous solution was freeze-dried and re-dissolved 
into 100 mL of water. The isoflavones were determined as previously described in 
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Chapter 2 (2.3.2.3). 
5.3.3 Animals 
Twenty-four (120 - 130 g) female Golden Syrian hamsters were housed (3- 4 
hamsters per cage) in an animal room at 2 5 � C with 12:12-h light-dark cycles. The 
animals were given free access to a stock diet (Glen Forrest Stockfeeds, Western 
Australia, Australia) for 10 days. All the hamsters were ovariectomized (Chonan et 
al, 1995) and waited for seven-day recovery from the operation before the 
experiment started. Blood (0.5 mL) was collected before and after the operation via 
the ophthalmic venous plexus. 
The ovariectomized hamsters were randomly divided into three groups. Six of 
them were assigned to the control (CTL), nine were assigned to soymilk group 
(OVX-SM) and nine were assigned to soybean extract group (OVX-SE). They 
were given free access to 0.1% cholesterol diet (Glen Forrest Stockfeeds, Western 
Australia, Australia). The OVX-SM group was given a single oral dose of soymilk 
(equivalent to 30 |xg isoflavones/ g body weight/ day). The OVX-SE group was 
given a single oral dose of soybean extract (equivalent to 30 |ig isoflavones/ g body 
weight), while the CTL was given a single oral dose of 2 mL of distilled water 
everyday. The body weight was recorded once a week, and food consumption was 
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recorded every 2 or 3 days. After 4 weeks of the experimental diets, feces were 
collected for 7 days. 
At the end of 4 weeks, all the hamsters were killed after overnight fasting. 
Blood was collected via the abdominal aorta. After clotting, the blood was 
centrifuged at 1500 g for 10 minutes and serum was collected. The liver, heart and 
kidney were also removed, washed with saline, and stored at -80 °C. 
5.3.4 Serum lipid determinations 
Serum TG, TC and HDL-C levels were determined as previously described in 
Chapter 3 (3.3.3). 
5.3.5 Determination of tissue cholesterol content 
The cholesterol content of animal tissues including liver, heart and kidney were 
measured as previously described in Chapter 3 (3.3.4). 
5.3.6 Extraction of neutral and acidic sterols from fecal samples 
The fecal neutral and acidic sterols were determined according to the method 
described by Czubayko et al (1991) with some modifications. The fecal samples 
were first dried in a lyophilizer and then grounded into powder. Stigmasterol (0.5 
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mg in 1 mL of chloroform) was added into a tube as an internal standard for total 
neutral sterols. The tube was dried down under a gentle stream of nitrogen. Then 
300 mg of grounded fecal sample and 0.5 mg hyodeoxycholic acid (0.5 mg in 2 Ml 
1 N NaOH) as an internal standard for total acidic sterols were added. The samples 
were then subjected to alkaline hydrolysis with 8 mL 1 N NaOH in 90% ethanol at 
90 °C for 1 hour followed by cooling down to room temperature. Then 1 mL of 
distilled water and 8 mL of cyclohexane were added to extract total neutral sterols. 
After centrifugation, the upper cyclohexane phase and the lower aqueous phase were 
separated, and the total neutral and acidic sterols were quantified as described below. 
5.3.6,1 Determination of neutral sterols 
The cyclohexane phase was evaporated to dryness under a gently stream of 
nitrogen. The neutral sterols were converted to their TMS-ether derivatives using 
TMS-reagent (dry pyridine-hexamethyldisilazane-trichlorosilane, 9: 3: 1，v/v/v，Sil-A 
regent, Sigma) at 6 0 � C for 1 hour. The mixture was then dried down under 
nitrogen stream and the TMS-derivatives of neutral sterols were dissolved in 400 |aL 
of hexane. After centrifugation, the hexane layer was transferred to a vial for GLC 
analysis. 
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5.3.6.2 Determination of acidic sterols 
For determination of acidic sterols, 1 mL of 10 N NaOH was added to the lower 
aqueous phase. The mixture was heated for 3 hours at 120 °C. Distilled water (3 
mL) was added to the mixture and cooled at room temperature. The mixture was 
acidified with 1 mL of 25% HCl. And the acidic sterols were extracted with 7 mL 
diethyl ether for two times. The ether phases were pooled and then dried down 
under a stream of nitrogen. Methylation of the acidic sterols was performed by 
adding 2 mL of methanol, 2 mL of dimethoxypropane and 40 |iL of concentrated 
HCl. The mixture was mixed thoroughly and allowed to stand at room temperature 
for overnight. The solvents were then dried down under a stream of nitrogen. 
TMS-reagent was added and heated at 60 °C for one hour to convert the acidic 
sterols into their TMS-ether derivatives. The mixture was dried down under a 
stream of nitrogen and the TMS-derivatives were dissolved in 300 |iL of hexane. 
After centrifugation, the hexane layer was transferred to a vial for GLC analysis. 
5.3.6,3 GLC analysis of neutral and acidic sterols 
The analysis of fecal neutral and acidic sterols was carried out in a GLC 
equipped with a fused silica capillary column as described in Chapter 3 (3.3.4). For 
the neutral sterols, the column temperature was set at 285 °C and maintained for 30 
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min. For the acidic sterols, the column temperature was programmed from 230 °C 
to 280 °C at a rate of 1 °C/ min. Helium was used as a carrier gas at a head 
pressure of 22 psi in both neutral and acidic sterol analysis. Typical chromatograms 
of neutral and acidic sterols were shown in Figures 5.1 and 5.2，respectively. 
5.3.7 Statistics 
Data are expressed as mean 士 standard deviation (SD). The group means were 
statistically analyzed using one-way analysis of variance (ANOVA) and Student's 
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Figure 5.1 Gas liquid chromatographic profile of neutral sterols in feces. 
Identification of peaks: 1，coprostanol; 2，coprostanone; 3, cholesterol; 4， 
dihydrocholesterol; 5, campersterol; 6，stigmasterol (internal standard) 
and 7，p-sitosterol 
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Figure 5.2 Gas liquid chromatographic profile of acidic sterols in feces. 
Identification of peaks: 1, lithocholic acid; 2, deoxycholic acid; 3, 
chenodeoxcholic acid; 4, cholic acid; 5，hyodeoxycholic acid (internal 
standard) and 6，ursodecholic acid. 
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5.4 Results 
5.4.1 Growth and food intake 
The body weight gain and food intake of hamsters are shown in Table 5.1. No 
significant differences in body weight, fluid intake and food intake were observed 
among the CTL，OVX-SM and OVX-SE groups. 
5.4.2 Effect of ovariectomy on serum TC 
Before and after the hamsters were ovariectomized, their total cholesterol was 
measured. The result showed that ovariectomization significantly elevated serum 
TC level (Table 5.2). However, no significant differences were observed among the 
CTL, OVX-SM and OVX-SE groups before SM and SE were given (Table 5.2). 
5.4.3 Effect of soymilk and soybean extract on serum TC, TG and 
HDL-C 
Significant reduction in serum TC was observed in the OVX-SM and OVX-SE 
compared with the value of the CTL group (P<0.01) (Table 5.3). To be specific, the 
serum TC in the OVX-SM and OVX-SE groups were 18% and 17% lower than that 
in the CTL hamsters, respectively. For the serum TG, the OVX-SM and OVX-SE 
were 6% and 13% lower than that in the CTL hamsters, respectively but the 
differences were not statistically significant. Soymilk or soybean extract had no 
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significant effect on the serum HDL-C level (Table 5.3) 
5.4.4 Effect of soymilk and soybean extract on non-HDL-C and 
ratio of non-HDL-C to HDL-C 
Non-HDL-C was defined as a difference between TC and HDL-C. Non-HDL-C 
levels for the CTL, OVX-SM and OVX-SE were 109.9 土 17.0, 81.8 士 9.4，78.6 士 
19.2 mg/ dL, respectively. A significant reduction in non-HDL-C by 26% and 28% 
compared with that in the CTL group was observed in the OVX-SM and OVX-SE 
hamsters (p<0.01)，respectively (Table 5.3). The ratio of non-HDL-C to HDL-C in 
the OVX-SE was found to be significantly lower than that of the CTL (Table 5.3). 
5.4.5 Effect of soymilk and soybean extract on concentration of 
hepatic cholesterol 
The livers were weighted immediately after the hamsters were scarified. The 
hepatic cholesterol in the CTL, OVX-SM and OVX-SE was 27.3 土 4.9, 24.5 士 4.9 
and 27.3 ± 3 . 4 mg/ g of liver, respectively. There was no significantly different 
among the three groups (Figure 5.3). 
5.4.6 Effect of soymilk and soybean extract on heart and kidney 
cholesterol 
There was no significant difference in heart and kidney cholesterol content 
among the three groups (Figure 5.4). 
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Table 5.1 Changes in body weight and food intake 
CTL (n=6) OVX-SM (n=9) OVX-SE (n=9) 
Initial body wt (g) 125.0 ±12.6 123.0 土 9.8 124.7 ±11.4 
Final body wt (g) 151.7 士 9.2 153.3 ±10.9 150.6 ±12.9 
Food intake (g/ day) 7.6 ±1.7 7.5 土 1.3 7.7 土 2.1 
Data are expressed as mean 士 S.D.; Number in parentheses indicates the number of 
hamsters used. 
98 
Table 5.2 Changes in serum total cholesterol (TC) before and after the hamsters 
were ovariectomized (mg/ dL) 
CTL (n=6) OVX-SM (n=9) OVX-SE (n=9) 
Before 97.5 ±2.6 95.6 ± 1.8 95.9 ±2.4 
After 142.7 ±6.5"" 147.6 ±4.5"*" 143.8 ± 5.4' 
Data are expressed as mean 土 S.D.; Number in parentheses indicate the number of 
hamsters used 
* differs significantly from the value before ovariectomization (P<0.01). 
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Table 5.3 Effects of soymilk (OVX-SM) and soybean extract (OVX-SE) on levels 
of serum triglycerides (TG), total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C), non-HDL-C and the ratio of 
non-HDL-C to HDL-C 
CTL (n=6) OVX-SM (n=9) OVX-SE (n=9) 
TG (mg/dL) 234.3 ±83.0 219.7 ±78.0 204.7 土 69.9 
TC (mg/dL) 225.3 ±7.7a 184.6 ± 26.8b 186.4 土 32.0b 
HDL-C (mg/dL) 115.5±15.7 102.7±18.6 107.8±16.2 
Non-HDL-C (mg/dL) 109.9 土 17.0a 81.8 士 9.4b 78.6 土 19.2b 
Non-HDL-C/ HDL-C 0.98 土 0.29" 0.81 士 O.OSab 0.73 土 0.14b 
Data are expressed as mean 土 S.D. 
Non-HDL-C = (TC) - (HDL-C) 
Means at the same row with different superscripts (a, b) differ significantly (p< 0.01) 
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Figure 5.3 Effects of soymilk (OVX-SM) and soybean extract (OVX-SE) on 
concentration of hepatic cholesterol in hamsters. Data are expressed 
as means 士 S.D. 
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Figure 5.4 Effects of soymilk (OVX-SM) and soybean extract (OVX-SE) on 
concentration of tissue cholesterol levels in hamsters. Data are 
expressed as means 土 S.D. 
102 
5.4.7 Effect of soymilk and soybean extract on fecal neutral and 
acidic sterols 
The neutral sterols refer to a sum of coprostanol, coprostanone, cholesterol, 
dihydrocholesterol, campersterol, and p-sitosterol. The total fecal neutral sterols 
were significantly elevated in the OVX-SM and OVX-SE hamsters compared with 
that in the CTL group (p<0.05). This result was due to the significant increase in 
the dihydrocholesterol (p<0.05) and campersterol (p<0.01) (Table 5.4). For other 
neutral sterols, no significant difference was observed among the three groups. 
The acidic sterols measured include lithocholic, deoxycholic, cholic and 
ursodeoxycholic acid. The total fecal acidic sterols were significantly elevated in 
the OVX-SM and OVX-SE hamsters compared with that in the CTL group (p<0.01) 
(Table 5.5). Among the individual acidic sterols, only lithocholic acid (p<0.05), 
cholic acid (p<0.05) and ursodeoxycholic acid (p<0.05) were found to be 
significantly increased in the feces in the OVX-SM and OVX-SE groups (Table 5.4). 
No significant difference was observed in the other acidic sterols among the three 
groups. 
103 
Table 5.3 Effects of soymilk (OVX-SM) and soybean extract (OVX-SE) on 
concentration of fecal neutral sterols (mg/ hamster/ day). 
CTL (n=6) OVX-SM (n=9) OVX-SE (n=9) 
Coprostanol 1.09 ±0.16 1.14 土 0.16 1.44 ±0.14 
Cholesterol 0.30 ±0.05 0.31 士 0.01 0.33 士 0.08 
Dihydrocholesterol 0.79 ±0.01� 0.84 ±0.03 0.90 ± 0.05a 
Campesterol 1.90 土 0.08b 2.35 土 0.03a 2.68 士 0.04" 
P-sitosterol 0.67 土 0.04 0.66 士 0.04 0.65 ± 0.12 
Total neutral sterols 4.75 士 0.10� 5.30 士 0.17a 6.01 士 0.36a 
Data are expressed as mean 士 S.D.，n=3. 
Means at the same row with different superscripts (a, b) differ significantly (p< 0.01) 
Means at the same row with different superscripts (a, c) differ significantly (p< 0.05) 
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Table 5.4 Effects of soymilk (OVX-SM) and soybean extract (OVX-SE) on 
concentration of fecal acidic sterols (mg/ hamster/ day). 
CTL (n=6) OVX-SM (n=9) OVX-SE (n=9) 
Lithocholic acid 0.30 士 0.06" 0.67 士 0.09a o . 4 4 士 0.05b 
Deoxycholic acid 0.01 士 0.02 0.00 士 0.00 0.03 土 0.02 
Chenodeoxycholic acid 0.17 ±0.10 0.15 ±0.13 0.28 ± 0.03 
Cholic acid 0.12 士 0.06� 0.30±0.04& 0.28±0.0ia 
Ursodeoxycholic acid 0.40 土 0.06c 0.55 士 0.05a o . 5 5 土 0.09a 
Total acidic sterols 1.00 土 0.02b 1.67 土 0.22" 1.59 士 0.09a 
Data are expressed as mean 士 S.D.，n=3. 
Means at the same row with different superscripts (a, b) differ significantly (p< 0.01) 
Means at the same row with different superscripts (a, c) differ significantly (p< 0.05) 
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5.5 Discussion 
Ovariectomization induced an increase in the serum cholesterol level in 
hamsters. The objective of this study was to investigate whether soymilk or 
soybean extract are effective in preventing the increase of blood cholesterol caused 
by ovariectomization. The present study demonstrated that oral doses of soymilk or 
soybean extract had a favorable effect on the serum cholesterol level. Soymilk or 
soybean extract could significant decrease serum TC and non-HDL-C in the 
ovariectomized hamsters, leading to a decrease in the ratio of non-HDL-C to HDL-C 
compared with the ovariectomized control. Also, supplementation of soymilk or 
soybean extract was associated with a decrease in serum TG although the difference 
among three groups was insignificant in the present study. 
There are multiple mechanisms by which the isoflavones in soymilk or soybean 
extract provide such a beneficial effect. The isoflavones are structurally similar to 
estrogen and bind to the estrogen receptor, so it is biologically plausible that they 
protect against atherosclerosis development as estrogen agonists. This mechanism 
may be via alterations in liver cholesterol metabolism (Sirtori et al., 1984)), resulting 
in the improvement of plasma lipids. A second potential mechanism is that 
genistein has antioxidant property, which has been proved in the previous experiment 
described elsewhere in the thesis. 
106 
Estrogen injection into ovariectomized rats reduced serum cholesterol level 
(Sato et al, 1996). A similar result was observed in the present study, suggesting 
that the hypocholesterolemic effect of soymilk or soybean extract was at least in part 
due to the estrogenic activity of the soybean isoflavones. 
Two recent studies examining isoflavone intake in humans have reported a lack 
of significant effect on plasma lipids and lipoproteins (Hodgson et al, 1998; Nestel 
et al, 1997). Results from these studies suggest that isoflavones alone do not 
improve plasma lipid and lipoprotein variables or impart the same CHD health 
benefits as intact soy protein. However, the present study demonstrated that both 
the OVX-SM and OVX-SE groups could improve plasma lipid and lipoprotein 
profiles. This study is in agreement with Kathryn et al (1999)，who found that the 
isoflavone extract of soy protein had a lipid-lowering effect. Therefore, caution 
must be exercised in extrapolating the results from animals to humans. 
The previous studies showed that estrogen increased HDL-C level and 
decreased LDL-C level in humans (Bruschi et al, 1996; Goldstein and Stampfer, 
1995). This was in contrast to the present study in which both the HDL-C and 
LDL-C were decreased. This discrepancy may be due to the difference in 
cholesterol metabolism between ovariectomized hamsters and postmenopause 
women. The present study clearly demonstrated that soymilk and soybean extract 
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could lower the ratio of LDL-C to HDL-C. This ratio is commonly used as a risk 
factor in assessment of cardiovascular disease. The higher the ratio, the greater the 
risk of cardiovascular diseases. 
The mechanisms by which soymilk and soybean extract lowered the ratio of 
non-HDL-C to HDL-C remained unexplored. One of the possible mechanisms may 
be associated with increased fecal excretion of total neutral and acidic sterols as 
observed in the present study. The result is in agreement with that reported by 
Potter (1996), who demonstrated that the dietary soy protein can enhance bile acid 
excretion in rabbits and rats. A decrease in intestinal cholesterol absorption has also 
been suggested as possible mechanism for the lipid-lowering effects of soy protein 
and/or soybean isoflavones (Nagata et al, 1982; Sugano et al, 1988). 
Soymilk or soybean extract may also increase in LDL receptor mRNA in 
mononuclear cells (Baum et al, 1998) and an increase in LDL receptor activity 
(Lovati et al, 1987; Sirtori et al, 1984). The increase in LDL receptor activity is 
very evident, following soy protein intake, in mononuclear cells isolated both from 
patients with familial hypercholesterolemia (Lovati et al, 1987) and also from 
postmenopausal women with moderate cholesterol intake. Recent data suggest that 
soy protein subunits, particularly 7S，one of the major storage proteins of soybean, 
directly activate LDL receptors in the human liver, thus providing a novel 
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mechanism of plasma cholesterol reduction different from currently available 
hypolipidemic drugs (Brooks and Morr, 1992). 
The present study in ovariectomized hamster, although not directly applicable to 
humans, may have some implications for postmanopause women who often consume 
soymilk and soya products. All data presented here suggest that drinking soymilk is 




Soybean is one of the major food sources in China. It is usually made and 
consumed in the form of bean curd and soymilk. Recently, many studies have been 
carried out to examine the health benefits of soybean. It is believed that isoflavones 
and their glycosides are the active components that are responsible for these health 
benefits of soybean. In the present study, seven isoflavones and their glycosides 
were isolated and purified from soybean, namely genistein, genistin, 
6"-0-malonylglycitin, 6"-0-malonylgenistin, daidzein, daidzin and glycitin. 
The ratio of non-HDL-C to HDL-C is commonly used as a risk factor of 
cardiovascular diseases. The higher the ratio, the greater the risk of cardiovascular 
diseases. By using hamster as an animal model, soymilk (SM) supplementation as a 
beverage could significantly lowered the ratio of non-HDL-C to HDL-C in hamsters 
fed a high cholesterol diet. In contrast, drinking cow's milk (CM) significantly 
increased the ratio. The hypolipidemic activity of soymilk compared with cow's 
milk was also reflected from the observation that serum TC was decreased when the 
hamsters were switched from cow's milk to soymilk. If the data could apply to 
humans, the decrease in the ratio of non-HDL-C to HDL-C indicated that drinking 
soymilk might be associated with a decreased risk of cardiovascular diseases. 
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Soymilk and soybean extract also had a favorable effect on the serum 
cholesterol level in ovariectomized hamsters. The soymilk and soybean extract 
could significant decrease serum TC and non-HDL-C, leading to a decrease in the 
ratio of non-HDL-C to HDL-C in ovariectomized hamsters fed a high cholesterol 
diet. Also, consumption of soymilk and soybean extract was associated with a 
decrease of serum TG in these hamsters. However, there was no effect on the 
concentration of cholesterol in the liver and other issues in both the OVX-SM and 
OVX-SE hamsters compared with the control group. These results strongly suggest 
that the hypocholesterolemic activity of soymilk and soybean extract is at least in 
part related to their estrogenic activity of the soybean isoflavones. 
The seven individual soybean isoflavones and their glycosides showed weaker 
antioxidant activity in Cu^^-mediated oxidation of human low-density lipoprotein 
(LDL) in vitro compared with a major tea antioxidant, epicatechin. A similar result 
was also shown in the FRAP assay. For the DPPH assay, the seven soybean 
isoflavones and their glycosides were less effective in scavenging free radicals than 
a-tocopherol. The present results clearly demonstrated that individual soybean 
isoflavones and their glycosides possessed antioxidant activity, but, their antioxidant 
potency was much weaker compared with that of epicatechin and a-tocopherol. 
In conclusion, soybean is rich in isoflavones and their glycosides. The 
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hypocholesterolemic activity of soymilk, together with its weak antioxidant against 
LDL-oxidation, suggests that soymilk is a potential healthy beverage in prevention of 
CHD. Soymilk may serve as an alternative to treat the hyperlipidemia, especially 
for those patients whose cholesterol level is marginally high not to warrant the 
prescription of cholesterol-lowering drugs. 
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